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 Foreword  
We are delighted to see the publication of this important and timely report. 
It is increasingly clear that developments in genomics and other emerging 
forms of data-driven medicine have the potential to significantly improve 
human health and to inform more effective and efficient health systems. At 
the heart of these developments is a recognition that the ability to 
provide the best medical care for individual patients can be greatly 
enhanced by comparing their data with that of many others. That is, 
through the faster sharing of knowledge. It is also clear that a modern 
and effective health service capable of offering best care will be one in 
which clinical practice and data-driven research are highly integrated. 
 
These benefits, which depend upon the collection, storage, and sharing 
of patient information are only fully achievable and sustainable in the 
context of well-founded public trust and confidence. That is, where 
patients, the wider public, health professionals, and researchers have 
shared expectations – a ‘social contract’ – about what constitutes 
reasonable and acceptable uses of patient data and samples. Any 
sustainable ‘contract’ of this kind will need to take the form of a 
relatively stable but nonetheless living dialogue capable of responding 
to the changes in medical science and technology and our shifting 
public attitudes and values. 
 
This report presents the results of an inclusive and thorough process 
of public dialogue and makes a vital and timely contribution to ongoing discussions in this area and 
to the achievement of the conditions for the successful and sustainable development of the NHS 
Genomic Medicine Service. It explores the perspectives of members of the public, patients, and 
experts from a range of public, private, and charity organisations to the collection, storage and use of 
health data for genomic medicine. It reveals that the relationship between the National Health 
Service, patients, and the public is currently understood in terms of three core values: reciprocity, 
altruism, and solidarity. This is welcome evidence of the endurance and continued relevance of values 
informing the original establishment of the NHS as a research active organisation. The findings of this 
dialogue suggest that these values are likely to continue to inform understanding of the appropriate 
relationship between medicine, research and society as genomic medicine plays a more central role. 
This report also emphasises the importance placed by participants on equity in both access to and 
outcomes of health services as a key component of the social contract for genomic medicine. 
 
There is no doubt that one of the most important factors in the recent success of the 100,000 
Genomes Project has been the embedding of ethics support and advice, and patient/participant 
involvement throughout the organisation and at all stages of the project. The Participant Panel and 
Ethics Advisory Group have played crucial roles in establishing and maintaining public confidence in 
the project. The findings published in this report help to illustrate why this might have been the case. 
The report is essential reading for everyone with an interest in the successful and appropriate 
establishment and future development of the NHS Genomic Medicine Service and of genomic and 
data-driven medicine more broadly. Given the profound importance of these developments and of 
Professor Dame Sally C Davies 
Chief Medical Officer for 
England and Chief Medical 
Advisor to the UK Government 
Professor Michael Parker 
Wellcome Centre for Ethics and 
Humanities, University of Oxford 
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the findings of this report, we very much agree with the authors’ recommendation that the ways in 
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 Executive summary  
 1. Introduction: a dialogue to capture public views of genomics  
The NHS Constitution reminds us that our health service is founded on a common set of principles 
and values that bind together patients, the public and staff so that it is effective and equitable. It 
recognises that each party has roles and responsibilities and therefore the Constitution can be seen as 
a form of ‘social contract’ which aims to bring the highest levels of human knowledge and skill to save 
lives and improve health.  
The Chief Medical Officer for England’s 2016 Annual Report, ‘Generation Genome’ argued for a re-
thinking of the wider social contract in healthcare today, taking into account four areas3 of medical 
and research practice. It also provided a public statement on the purposes and benefits of genomic 
data in the NHS. Chapter 164 of the report draws together the important requirements that need to 
be in place if genomic medicine is to be ethically and socially acceptable to the UK population.  
The purpose of this dialogue was to take into account members of the public’s priorities and concerns 
when considering how genomics might alter or affect the social contract in healthcare. This was in 
order to inform the way genomics should be mainstreamed in the NHS in England, as well as to 
inform healthcare policymaking in Scotland, and the future of genomics more broadly.  
Why was a Sciencewise public dialogue the most suitable approach to canvass the public’s views on 
a genomics future?  
A Sciencewise public dialogue provides in-depth insight into citizens’ views, concerns and 
aspirations on issues relating to science and technology5. These issues are often complex and 
unfamiliar to citizens and therefore their exploration is better suited to a qualitative approach.  
How are this dialogue’s findings valid?   
Applying criteria used in the social science literature6 to determine the credibility of qualitative 
research findings, we can be confident that the principles and views presented here are credible 
and valid due to the following strategies used in this dialogue:  
a) accounting for researcher bias – in order to ensure the information given to the dialogue 
participants was balanced, we engaged with a diverse range of expert perspectives, 
including data privacy campaign groups, all of which fed into the development of the 
research materials and stimulus.     
b) accounting for sampling bias – the dialogue participants were recruited to be reflective of 
the wider UK population, using quotas informed by UK census data.  
c) accounting for research bias – participants were given all the information to enable them to 
develop their views, and given time to reflect between events. Experts rotated to each 
discussion group to ensure the participants were exposed to the same sort of information. 
Plenary sessions were built in to each event so we were able to identify a range of views 
including commonalities and outliers.   
                                                     
3 The four areas are: consent, confidentiality and the availability of the best care for patients and families, obligations of health professionals, 
lab staff and researchers; system responsibilities. 
4 Lucassen, A. Montgomery, J. Parker, M. (2016) ‘Ethics and the social contract for genomics in the NHS’ in Annual Report of the Chief 
Medical Officer 2016: Generation Genome (Published by the Department for Health and Social Care).  
5 https://sciencewise.org.uk/about-dialogue/what-is-public-dialogue/  
6 https://ebn.bmj.com/content/18/2/34  
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d) meticulous record keeping and systematic analysis – a transcript was produced from each 
discussion group, with each one analysed using qualitative social science technique. A series 
of analysis sessions attended by the Ipsos MORI team, the independent evaluator and 
Genomics England has ensured that all the different perspectives are represented in this 
report.  
e) participant and expert validation – bringing participants back to a final genomics summit 
enabled us to explore key issues in further detail and thereby validate the views we noted in 
previous workshops. Experts who observed and participated in the dialogue discussions 
have reviewed the report and given feedback.  
f) data triangulation – the views and perspectives of the dialogue participants are supported 
by the rapid evidence review, and other relevant research, all of which are referenced 
throughout this report, where appropriate.  
Are these findings representative / generalisable? This dialogue sought to understand the depth 
and complexity of views on a genomic medicine service and the impact of information on these 
views.  In contrast with quantitative approaches, dialogue findings are not statistically significant. 
However, dialogue enables us to explore the values and reasons underlying the views expressed. 
How is this public dialogue useful to decision-makers? A dialogue is a valid and robust way to 
inform policy, especially to inform understanding of the range of options open to policy makers 
which will fit with the sensibilities of the public; and why the public think the way they do. The 
culmination of this public dialogue is this report which provides detailed and nuanced evidence on 
how citizens’ views, concerns and aspirations can be operationalised in a genomics future. 
 
Ninety-seven members of the public, and thirty experts came to evening and reconvened day-long 
Saturday events in Coventry, Edinburgh, Leeds, and London. A proportion of each group was 
reconvened to a final Genomics summit event in London (n=23 in total), where the group was again 
joined by experts.  A total of forty-three experts attended the dialogue workshops and the Genomics 
summit. The sessions were facilitated by a team from the Ipsos MORI Public Dialogue Centre. 
A rapid literature review was conducted to inform the dialogue materials and to ensure that the 
project built on the work of previous social research on attitudes to genomics.  The structure of the 
dialogue was developed in partnership with the Oversight Group, and materials and key questions 
were workshopped prior to the dialogue workshops with an external group of 15 stakeholders 
reflecting a range of perspectives. 
 2. Public views of the healthcare social contract  
The dialogue participants were not familiar with the term ‘social contract’ or the explicit concept to 
which it refers. However, when participants discussed during the dialogue how they think healthcare 
works now, and how genomics should operate in society, their responses were predicated on 
assumptions about the social contract that they believe to be in place.  We are therefore able to draw 
out the ingredients they feel this contract should have. Chapter 2 discusses this in detail. 
First, they had some clear perceptions of how they felt the social contract works today (before 
considering the idea of genomics). They saw it including three elements; reciprocity, altruism, and 
solidarity.  
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Reciprocity meant a ‘transactional relationship’ in which users “give” and “get”. Expectations were: 
• The NHS will provide evidence-based care.  
• Patients are given diagnoses and information about their condition, and the chance to discuss 
this with their doctor.  
• Doctors are trusted to only share patient information and data with those who are directly 
involved in a patient’s care.  
• The Government’s role is to manage and deliver healthcare services efficiently, through taxes 
collected centrally.  
• Users (patients and the wider public) are expected to behave well (e.g. to not abuse NHS 
staff), to value resources (e.g. turn up for appointments on time) and support the NHS; 
understand and appreciate the value of the care given.  
The social contract also requires altruism: 
• Members of the public are expected to want to benefit others as well as themselves, and 
behave altruistically (e.g. donating blood, letting ambulances through traffic).  
• Participation in health research (when understood) was seen as an altruistic act, as it often 
does not deliver immediate individual benefits. 
• The NHS should provide healthcare services that are free at the point of delivery; regardless of 
a person having UK citizenship; there was an inbuilt moral stance that it would be wrong to 
deny care to anyone, especially emergency care.  
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Solidarity was the third key aspect of the social contract, requiring:  
• A shared acceptance of paying for healthcare by progressive taxation. 
• Public acceptance that individual good health contributes to the public good, and complying 
with health instructions (e.g. vaccinations) to reduce the public health burden.   
• The NHS is expected to carry out effective triage7, so that patients priority for treatment is 
based on clinical need.  
• Clinicians exercising a moral and ethical duty to treat everyone equally and with respect. 
Importantly, in dialogue participants’ conception of the social contract, expectations of researchers 
were often absent; and the role of commercial companies was ignored. This reflects the fact that the 
general public are generally not aware of the role biomedical research plays in the healthcare system, 
or the role that charities, industry, and others play in the existing system. 
 3. What genomics might add to the social contract  
By the end of the dialogue, participants had discussed the implications of genomics for the social 
contract.  Overall, in a genomics-driven healthcare of the future, they felt the principles of reciprocity, 
altruism and solidarity would need to remain core to the social contract, and require largely the same 
behaviours of all the actors. 
However, the new science of genomics means that the three elements might intersect in new ways - 
leading to new expectations of behaviours of all actors in the system.  
 
                                                     
7 The category assigned to a patient as a result of an initial assessment by medical or nursing staff in an Accident and Emergency 
Department. The triage category is used to determine the patient’s priority for treatment, and to inform the patient of their waiting time. 
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• Reciprocity   Altruism: Analysing an individual’s genome requires that data has been 
donated by many. This is because an individual’s data needs to be compared against that of 
others to properly inform their diagnosis and treatment.  This blurs the line between 
reciprocity and altruism. The public in the dialogue saw giving their data as an altruistic act - 
but also expected benefits would probably accrue to their families and descendants.    
o There would, therefore, be an increased expectation that the public would donate 
data, but participants felt that data donation should not be mandatory. 
o Participants thought that government and healthcare policy makers would need to 
create a roadmap for genomics where the status of data donors is made clear, and 
any rewards for them carefully worked out. 
• Reciprocity   Solidarity: Genomics can use patient data in research and clinical care at the 
same time, creating a feedback loop between both to increase possible learning.  Participants 
felt that this research/clinical blurring brought the ideas of reciprocity and solidarity closer 
together. 
o Both clinicians and researchers in a genomics future would be responsible for ensuring 
that patients and families are informed about the progress of research. 
o They should also focus on translating the benefits of research into care, to help all of 
society, as quickly as possible.  
o Both researchers and clinicians should communicate to the public what they are doing 
with genomic data, and the link between their work and making discoveries with 
clinical impact; so the public can know their collective action is worthwhile and having 
impact.  
• Solidarity   Altruism: In the future, if large genomic datasets exist, and can potentially be 
accessed by new actors (such as commercial companies) social solidarity will be affected by 
the altruistic acts of individual donors.  Dialogue participants felt that: 
o Policy makers should take the long view – design a future which prevents dystopian 
social outcomes. Participants emphatically did not want their donation of genomic 
data used outside of healthcare and research in ways that would create a stratified 
society which disenfranchises vulnerable members. (e.g. using predictive genomic 
testing when a person applies for insurance) or different racial or ethnic groups. 
o There would be a new role for industry in bringing the benefits of genomics to society; 
but either voluntary or external regulation will be needed. Again, participants did not 
want to see the altruistic data donations of individuals used to enable private sector 
profiteering. 
 4. What genomics might change about the social contract  
As well as these additions, participants also felt there would be one change to the social contract; 
genomics changes the expectation that clinicians will only share data with those involved directly in 
patient care.  This leads to new duties of care for both researchers and clinicians. 
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• Participants wanted to empower clinicians to make the final decisions on disclosing 
information (for instance, to family members affected by test results). However, participants 
acknowledged that this was not an easy recommendation to make, and often changed their 
views on whether there should be a general policy or whether clinicians should judge on a 
case-by-case basis. On one hand they wanted decision-making to be shared with patients and 
very transparent, and they wanted patients to be able to challenge decisions they did not 
agree with. Yet on the other hand, they did not want to add any administrative burden on 
clinicians from a medico-legal perspective, which making such decisions would involve. 
• After deliberation, participants were broadly happy to accept the uncertainty of not knowing 
what information genomics might reveal, and trade off complete confidentiality against 
potential benefits for themselves and others, as part of their broad consent to participate in 
genomics research. 
Participants felt both clinicians and researchers should be equipped with “genomic literacy” to 
support the informational, emotional and practical needs of patients and data donors; giving more 
information and support than has been necessary in the past when communicating with research 
participants.    
 5. Red lines: unacceptable uses of genomic data  
Participants had some clear limits for how far they thought genomic data, and information derived 
from genomic analysis, should be used. 
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• Genetic engineering: Participants saw huge ethical issues around editing the human genome, 
especially to enhance human capabilities. They wanted to prevent this happening, at least 
without much more public engagement around the uses of genomic data.  
• Surveillance society: many participants had a sense of fatalism that the day would come when 
genomic data would be used, either by corporate interests (e.g. insurance) or by the state (e.g. 
crime and justice and taxation) to stratify society in order to identify and penalise individuals 
with acute healthcare needs, and unfairly monitor groups in society; they wanted to prevent 
this. 
• Administrative and political uses: there was a general feeling that more data is being collected 
all the time which has the potential to be used in ways which reduce access to state funded 
services such as welfare, and create a general sense of control in society; participants wanted 
to prevent this.  
• Predictive insurance tests: participants were not supportive at all of using genomic information 
to set personal insurance premiums 
• Targeted marketing: participants were very clear that data should not be used for marketing, 
or other areas of product development which might enable profiteering, especially by 
international corporates.   
Participants wanted assurances from policy makers, the government, as well as independent 
stakeholders (e.g. data privacy campaign groups) that there is a robust governance framework in 
place which ensures their red lines don’t happen in practice, which incorporates a consent process 
that makes it clear what researchers intend to do with genomic data.  
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 6. Communicating genomics as a collective endeavour in healthcare  
This dialogue suggests that the public are likely to be open and welcome to the idea of using 
genomics more widely in healthcare.  
• Initially, participants had a limited understanding of genomics; almost nobody had heard of a 
‘genome’ or ‘genomics’. When introduced to the ideas, however, almost all responded 
positively and many developed high expectations of genomics, envisaging a near-term future 
with new treatments and personalisation of care, and significant cost savings for the NHS. 
Others were initially worried about who would be using their genomic data and for what 
purposes even though they could recognise the benefits of their genomic data being used in 
health research.  
• Almost all were relaxed about their health and genomic data being used in health research. 
This support is, however, conditional on consent being obtained first; the use of de-identified 
data only and red lines being respected; robust risk assessment and safeguards being 
implemented and maintained by policy makers, researchers and clinicians; and genomics seen 
to be having real clinical impact.  
Realising the potential of genomics in the longer term will require a critical mass of UK citizens 
supporting it to the extent they are willing to participate. While this is a longer-term aim, creating and 
implementing a genomics narrative should be an immediate priority as the dialogue participants were 
clear that policy makers and the NHS have a responsibility to do more to inform people about 
genomics.  
 
The narrative on genomics will need careful framing, because, if the benefits of genomics are over-
hyped, or the uncertainties or limitations downplayed, there is a risk of fracturing the public’s trust in 
genomics, and in health research more generally. Communications should convey the idea that 
genomics is an ambitious, potentially ground-breaking programme of activities that aims to:   
• redefine what best care is: for example genomics is moving away from “one size fits all” 
treatments to patient care tailored to their unique genetic make-up  
• deliver new medical discoveries 
• but also change healthcare in ways which cannot be predicted with certainty. 
 
It should not be confused with a service like blood or organ donation; a key misunderstanding in 
discussions.  Instead, communicating the idea of a “national moonshot” or shared endeavour may 
work to link genomics to a wider UK programme of innovation in which we are all involved.   
 
In the longer-term as genomic medicine is scaled-up, genomics will need a call to action - if a social 
contract around genomics is going to work the public need to know what genomics is and be 
motivated to take part, so there is a need for a mission statement that conveys the idea that success 
needs solidarity, altruism and reciprocity. We can infer from the participants’ discussions that the 
following statement might work as a call to action, as well as communicate the essence of the social 
contract in an intelligible way.   
“People powered genomics”. 
 
As genomics evolves, further public and stakeholder engagement may be needed to ensure the social 
contract remains relevant and useful.  
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Genomics England with support from Sciencewise, commissioned Ipsos MORI to undertake a series of 
public dialogue workshops exploring how the public feel that genomic medicine should best be 
‘mainstreamed’ into the NHS. The project involved exploring the principles the public believe should 
underlie any ‘social contract’8 between the public and providers of genomic medicine. 
1.1 What is genomics?  
Over the last decade, genomics has rapidly accelerated as an area of clinical relevance, with major 
advancements within our diagnostic capabilities of rare diseases, alongside greater efficacy when 
prescribing medication. The future potential of genomics is huge, with increasingly accurate and 
sophisticated diagnostic techniques alongside better therapeutic possibilities for many diseases. 
1.2 Genomics in the NHS and the Generation Genome report 
In 2012, the Department of Health and Social Care launched the 100,000 Genomes Project and 
founded Genomics England9, as an independent company whose sole shareholder is the Secretary of 
State for Health, to coordinate the project. The aim of the 100,000 Genomes Project was to collect and 
analyse 100,000 genomes from 70,000 people. Those invited to take part were patients with certain 
kinds of cancers, and rare10 or unknown diseases. In those with cancers, a genomic sample was taken 
from both healthy (non-cancerous) cells and cancerous cells. The Project reached its target of 
sequencing 100,000 genomes in December 2018.11 
As a result of the success of the 100,000 Genomes Project, NHS England is establishing infrastructure 
to mainstream genomic medicine across the NHS.  The genomic testing available and the criteria for 
access is defined as part of the National Genomic Test Directory12. Genomic tests are also available to 
patients in Scotland, Wales and Northern Ireland through different NHS systems.  
A key aspect of the infrastructure in England is seven Genomic Laboratory Hubs that will co-ordinate 
and deliver genomic testing for patients covering defined areas of the country. In addition, the UK 
government has recently announced its intention to analyse a further five million genomes, as part of 
its effort to grow the database upon which genomic research can draw.13 
The Chief Medical Officer for England’s 2016 Annual Report, ‘Generation Genome’, sought to explore 
the potential of genomics within the health and social care system. The report provides a public 
statement on the purposes and benefits of genomic data in the NHS. It argues for a re-thinking of the 
wider social contract in healthcare today, taking into account four areas14 of medical and research 
practice.  
                                                     
8 To ensure the dialogue participants could engage with the concept of a social contract for genomics, a working definition was formed for 
the purpose of this dialogue: “The shared, reasonable assumptions and expectations that everyone in the system has, which guide how the 
[genomics] system works 
9 https://www.genomicsengland.co.uk/  
10 For patients with rare diseases, their parents also had their whole genome sequenced.  
11 https://www.genomicsengland.co.uk/the-uk-has-sequenced-100000-whole-genomes-in-the-nhs/  
12 https://www.england.nhs.uk/publication/national-genomic-test-directories/  
13 https://www.gov.uk/government/news/matt-hancock-announces-ambition-to-map-5-million-genomes  
14 The four areas are: consent, confidentiality and the availability of the best care for patients and families, obligations of health 
professionals, lab staff and researchers; system responsibilities.  
1 Introduction  
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In the light of this report, Genomics England with support from Sciencewise considered it important 
to canvass the views of the public on their hopes and priorities for genomics, as well as their views on 
the potential changes to, or evolution of, the social contract.  
1.3 The dialogue aim and objectives 
The overall aim of this dialogue was to engage the public in a dialogue to gain a greater 
understanding of the public aspirations, concerns and expectations of genomics and genomic 
medicine.  
In this context, the public dialogue sought to explore the following objectives.   
 Establish current knowledge and understanding on public views and attitudes to i) genomic 
medicine, ii) whole genome sequencing iii) the concept of a ‘social contract’ between the 
public and the NHS and iv) safeguards/’red lines’ essential to public support/trust for genomic 
medicine, through a review of previous dialogue, engagement, consultation and related 
research projects involving the public. 
 Understand participants’ aspirations and concerns around the use of genomic data and other 
personal information. 
 Understand how participants ‘trade off’ concerns about data, privacy and use of their 
information against potential health and other benefits that may come from genomic 
medicine, and what safeguards need to be in place. 
 Explore understanding of the idea of a ‘social contract’ as applied to the NHS and the 
principles by which it is understood to, or should, operate. 
 Explore what expectations and understanding are shared between patients, the public, 
clinicians, academics, industry and other stakeholder groups around the ambitions and 
outcomes for genomics and genomic medicine in the UK. 
 Contribute to and inform the ongoing policy, political and ethical environment for genomic 
medicine to flourish, as the benefits and opportunities presented by the technology are 
realised. 
 Contribute to the wider policy, political and ethical environment about the collection and use 
of data by government beyond healthcare and genomics. 
 Develop an understanding of the language and terms that the public and other stakeholders 
use in association with genomic medicine in order to inform communications for and about 
genomic medicine activities and services in the UK. 
1.4 Study design 
The dialogue was intended to build on existing research on public attitudes to genomics, and fill gaps 
in existing understanding. As such, Ipsos MORI conducted a rapid literature review15 in August 2018, 
which showed what is already known by the public, and also the views of experts, clinicians, and 
                                                     
15 https://www.genomicsengland.co.uk/what-do-we-know-about-public-attitudes-to-genomics/ 
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patients on some of the ‘live issues’ in genomics. The findings were shared with the Oversight Group 
and Stakeholder Group (see below) and feedback was used to inform the materials used in the 
dialogue workshops.  
An Oversight Group (OG)16 provided guidance to the dialogue: the group was comprised of clinicians, 
academics, policy makers, patients and representatives from a range of public, private and third 
sector organisations who play a part in genomics. The group’s role was to help shape and steer the 
project, and use their collective expertise to advise on the technical, ethical and practical issues 
associated with genomics.   
In September 2018, Ipsos MORI organised a Stakeholder Group17. This group contained a broader 
range of experts and stakeholders within genomics and helped capture a greater diversity of voices 
within the area. Their views, along with those from the Oversight Group, helped ensure the 
information presented to the public was balanced and technically accurate.  
Ninety-seven members of the public, and thirty experts came to evening and reconvened day-long 
Saturday events in Coventry, Edinburgh, Leeds, and London. These locations were chosen to reflect 
the diversity of geographical areas in England and Scotland. The workshops took place between 
October and November 2018.  
Participants were recruited to be reflective of the population of each of the four areas.  To achieve 
this, we designed a quota for gender, age, ethnicity, working status, and socioeconomic grade. Note 
that this sample should not be taken as representative from a statistical point of view. Instead the mix 
of participants aimed to reflect the mix of people in and around each location.  
Public participants were given a cash honorarium. This is standard in Sciencewise dialogues and is 
done to ensure that a diversity of participants are able to attend the event regardless of financial 
circumstance. For this reason also, the day-long events were held on a Saturday. 
At each location we met with the participants twice: at an evening event where we introduced 
genomics, and a full-day long workshop where we could explore the material in greater depth. Each 
table at the workshops was facilitated by the team at Ipsos MORI.  
The workshops in Edinburgh took place in a slightly different context. The key difference between 
Scotland and England is that the NHS Scotland and its partners18 are considering how to make best 
use of genomic testing in the future. Genetic tests already take place routinely in NHS Scotland, 
including exome testing19, but the efficacy of whole genome testing is still being assessed through 
research. Canvassing public views is an important part of this work.   
1.4.1 The structure of the workshops  
Informing the dialogue participants about genomics, genomic medicine, and the different actors who 
will play a part in it was an important first step, given the limited understanding of genomics among 
the UK population (see Section 3.1).  
                                                     
16 A full list of Oversight Group members is included in the Acknowledgements section.  
17 This included patient group representatives, data privacy campaign groups, social scientists, and representatives from pharma and med-
tech companies.  
18 Such as Scottish Government and Scottish Genomes Partnership. 
19 Next-generation sequencing techniques “read” all of the DNA in a person’s genes letter by letter (all 3 billion of them) to allow 
comparisons to be made with the DNA of other people. Exome sequencing is the targeted analysis of the gene regions that code for 
protein. Whole genome sequencing examines the entire genetic code of an individual. As researchers learn more about what individual 
DNA changes can mean for health and disease, information provided by these techniques will be used by the NHS to provide new 
diagnoses and treatments. 
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Day-long follow-up sessions exposed the dialogue participants to a range of expert perspectives with 
regard to the benefits which may arise from genomics, its uncertainties, and potential risks, as well as 
the ‘live’ ethical and practical issues such as consent and patient confidentiality,  
Engaging the dialogue participants through extended and staggered events meant they were able to 
deliberate and develop more considered opinions on the usage of genomic data, the responsibilities 
and obligations of different genomic actors, and the assurances/messages which are likely to 
encourage genomic data donation. 
At each location interactions with participants consisted of the following: 
Evening event 
• Discussion around healthcare – 
hopes and priorities  
• Plenary presentations and table 
discussions to introduce 
genomics and genomic 
medicine  
• Discussion of hopes and fears 
on genomics / genomic 
medicine  
 
Day-long workshop event 
• Genomics expert presentations 
• Scenario-based family trees (using visual 
illustrations). These different family trees 
allowed the public to engage with abstract 
ethical and practical issues associated with 
genomics 
• Discussion of a social contract in genomics 
• Discussion of genomic data: consent, 
confidentiality, security and safeguards, 
and red lines  
1.4.2 The role of experts in this dialogue  
Alongside members of the public, a number of experts were invited to each event. They were all 
people with significant experience of genetics/genomics either as clinicians, researchers, or genetic 
counsellors. Their role was to help clarify any technical questions asked by dialogue participants, 
explain what practical and ethical issues exist in genomics, how those issues are handled, and engage 
alongside the public in discussions about a new social contract for genomics. In addition it was an 
opportunity for them to directly hear some of the issues raised by public participants.  
Having participants from the 100,000 Genomes Project join in the dialogue workshops engaged the 
public with the lived experience of having a genetic condition, and the idea of familial implications. 
Their input brought a sense of realism to the high expectations that participants had for genomics at 
the outset. 
Table 3: Experts who attended and contributed at a dialogue event  
Name  Role  Organisation  Event location  
Simon Wilde  Communications Manager  Genomics England  London event 1 
Tom Fowler Deputy Chief Scientist and Director 
of Public Health 
Genomics England London event 1 
Sarah Caffery 100,000 Genomes Project Participant  N/A London event 1 
Dr. Lea-Rebecca 
Lahnstein  
Genomics England Clinical 
Interpretation Partnership (GeCIP) 
Cross-Cutting Coordinator 
Genomics England London event 1 
Christine Patch Consultant Genetic Counsellor Department of Clinical 
Genetics at Guy’s & St 
London event 2  
Ipsos MORI | A public dialogue on genomic medicine – FINAL – Public 20 
 
18-045132-01 | FINAL | Public | This work will be carried out in accordance with the requirements of the international quality standard for Market Research,  
ISO 20252, and with the Ipsos MORI Terms and Conditions which can be found at http://www.ipsos-mori.com/terms. © Ipsos MORI 2019 
 
Thomas’ NHS Foundation 
Trust 
Dr Richard Scott Consultant in Clinical Genetics, Head 
of Rare Disease Programme 
Genomics England London event 2 
Professor Tim 
Hubbard 
Professor of Bioinformatics, Head of 
Genome Analysis 
King's College London, 
Genomics England 
London event 2 
Lisa Dinh  Senior Communications Manager Genomics England  London event 2 




100,000 Genomes Project Participant  N/A Coventry event 
1 
Ann Dalton Consultant Clinical Director Sheffield Children’s NHS 
Foundation Trust 
Coventry event 
1 and event 2  
Dr Felicity 
Boardman 
Assistant Professor Division of Health 




Sean James Arden Tissue Bank Manager & South 
Midlands Genomics Ambassador 
 
University Hospitals 
Coventry & Warwickshire 
Coventry event 
2  
Katherine Mazur Genetic Counsellor Birmingham Women’s and 




Simon Wilde  Communications Manager  Genomics England  Leeds event 1 
Dr Mushtaq 
Ahmed 
Manager Genetic Counsellor Leeds Teaching Hospitals 
NHS Trust 
Leeds event 1  
Kate Grafton Principal Lecturer Leeds Beckett University Leeds event 1  
Dave McCormick 100,000 Genomes Project Participant  N/A Leeds event 1 
and event 2  
Andy Hart 100,000 Genomes Project Participant  N/A Leeds event 1 
and event 2  
Prof Eamonn 
Sheridan 
Professor of Clinical Genetics University of Leeds Leeds event 1 
and event 2 
Prof Colin Johnson  Professor of Medical and Molecular 
Genetics  
University of Leeds  Leeds event 2 
Dr Jon Fistein Associate Professor in Clinical 
Informatics 
Leeds Institute of Health 
Sciences 
Leeds event 2  
Saghira Malik Principal Genetic Counsellor  Leeds Teaching Hospitals 
NHS Trust 
Leeds event 2  
Cheryl L Stopford Genetic counsellor  NHS England  Leeds event 2 
Stephanie Hart  Genetic counsellor  NHS England  Leeds event 2  
Prof Zosia 
Miedzybrodzka 
Professor of Medical Genetics University of Aberdeen Edinburgh 
event 1  
Prof David 
Porteous 
Chair of Human Molecular Genetics 
& Medicine 
Centre for Genomic and 
Experimental Medicine, 
University of Edinburgh 
Edinburgh 
event 1  
Dr Wendy Inglis 
Humphrey 
Project Manager, Scottish Genomes 
Partnership 
Centre for Genomic and 
Experimental Medicine, 
University of Edinburgh 
Edinburgh 
event 1 and 2  
Simon Wilde  Communications Manager  Genomics England  Edinburgh 
event 2 
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Dr Victoria Svinti 
MacLeod 
Bioinformatician  MRC Human Genetics Unit, 
University of Edinburgh 
Edinburgh 
event 2 




100,000 Genomes Project Participant  N/A  Edinburgh 
event 2 
Joana Gomes Genetic counsellor  NHS Grampian  Edinburgh 
event 2 
1.4.3 A Genomics Summit  
The Genomics summit took place in December 201820. This event was an opportunity to create a 
lively, informed conversation between experts, patients and the public21, and explore areas in even 
greater depth than had been possible at the previous events. Participants rotated around five stations 
set up in a large room, each one exploring a particular aspect of genomics:   
• Station #1: Where is our data? – participants were asked to reflect upon usage of genomic 
data, and what assurances are needed to encourage data donation.   
• Station #2: The patient of the future – in light of the anticipated benefits arising from 
genomics as well as its uncertainties and limitations, participants deliberated on what 
behaviours they would expect from the different genomic actors.      
• Station #3: One big family – given the genetic test result has familial implications, this station 
asked participants to consider the implications for consent and patient confidentiality, and 
how patient information and emotional needs should be met in genomic medicine.  
• Station #4: Show me the money – this station explored what participants expect from 
genomic medicine both in terms of access and outcomes.  
• Station #5: Blurred lines – this station looked at what people expect from clinicians and 
researchers (including those in commercial companies) given research and clinical practice 
come together in genomics  
Participants were able to engage with a mix of stimulus materials (e.g. mocked-up newspaper 
headlines), real world resources (e.g. 100,000 Genomes Project consent forms); and props (e.g. a data 
‘black box’), before moving to the next station. After each section, final thoughts were written in a 
booklet prepared for the event.  
Table 4: Members of the Oversight Group and Stakeholder Group and experts who attended and 
contributed to the genomics summit.   
 Name  Role  Organisation  
1 Vivienne Parry  Head of Engagement Genomics England  
2 Professor Jonathan 
Montgomery  
Professor of Health Care Law UCL Faculty of Laws, University 
College London 
3 Dr Mark Bale Deputy Head of Health Science and Bioethics Department of Health 
4 Dr Natalie Banner Lead Understanding Patient Data 
5 Phil Booth Coordinator Med Confidential 
6 Pete Mills Assistant Director Nuffield Council on Bioethics 
7 Freddie Baker Lead Policy Officer Information Commissioners Office 
                                                     
20 A total of forty-three experts attended the dialogue workshops and the Genomics summit. 
21 Participants (n=7 from each) from the London, Coventry and Leeds workshops were invited back to a half-day-long Summit which was 
held in London.  
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8 Monika Preuss Head of Genomic Science, Genomics and 
Emerging Technologies 
Department of Health and Social 
Care 
9 Rose Gray  Policy Manager  Cancer Research  
10 Louise Coleman  Policy Manager  Genetic Alliance  
11 Sandy Shaw  Communications Manager Progress Educational Trust  
12 Ann Dalton Consultant Clinical Director Sheffield Children’s NHS 
Foundation Trust 
13 Shahid Hanif  Consultant  Association British Pharmaceutical 
Industry  
14 Fiona Maleady-Crowe  Head of Ethics  Genomics England  
15 Simon Wilde  Communications Manager  Genomics England  
16 Dr Wendy Inglis 
Humphrey 
Project Manager, Scottish Genomes 
Partnership 
Centre for Genomic and 
Experimental Medicine, University 
of Edinburgh 
1.5 Interpretation of findings  
As noted in the executive summary, applying criteria used in the social science literature22 to 
determine the credibility of qualitative research findings, we can be confident that the principles and 
views presented here are credible and valid due to the following strategies used in this dialogue: 
accounting for bias, meticulous record keeping and systematic analysis, validation and data 
triangulation. The culmination of this public dialogue is this report which provides detailed and 
nuanced evidence on how citizens’ views, concerns and aspirations can be operationalised in a 
genomics future. 
For reporting on dialogue we use the conventions of qualitative social science reporting:  
• We indicate via "a few" or "a limited number" to reflect views which were mentioned 
infrequently and “many” or “most” when views are more frequently expressed. We use “some” 
to reflects views which were mentioned some of the time, or occasionally.  Any proportions 
used in our reporting should be considered indicative, rather than exact.  
• However, we also indicate strength of feeling even when views are expressed by a minority, as 
this may also give useful insight into the range of feelings which exist within different groups 
of people.  
• We are reporting perceptions rather than facts; in the case of this project there are various 
misconceptions our participants expressed about questions of fact, for example lack of 
understanding of legislation around data protection, and low awareness of biomedical 
research and its technical processes. We have indicated where we are reporting perceptions of 
participants, and where we are offering analysis of the implications of these perceptions.  
• Where views apply only to a subset of participants, e.g. participants in London, we highlight 
this in the text. 
 
1.5.1 Stylistic conventions  
We have used the convention of describing the word data in the singular rather than plural, plus the 
terminology around patient data recommended by Understanding Patient Data23 (e.g. ‘data or 
information about you’ rather than ‘health information’; talking about individual care rather than 
clinical care; and describing data as either personally identifiable or depersonalised).   
                                                     
22 https://ebn.bmj.com/content/18/2/34  
23 http://understandingpatientdata.org.uk/  
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2.1 Public views of key behaviours in the social contract now  
The NHS Constitution is founded on a common set of principles and values that bind together 
patients, the public and staff in order to ensure that it can be effective and equitable. It recognises 
that each party has important rights that must be respected, but also that each owes each other 
responsibilities.  
Through this combination of reciprocal rights and obligations the NHS aims to operate fairly and 
effectively for mutual benefit. The NHS Constitution is thus the expression of a form of ‘social 
contract’ which aims to bring the highest levels of human knowledge and skill to save lives and 
improve health.24 
The dialogue participants were not familiar with the term ‘social contract’ or the explicit concept to 
which it refers. However, when dialogue participants discussed how they think healthcare works 
today, and how genomics should operate in society, through the dialogue, they underpinned their 
responses with assumptions about a clear social contract that they believe is in place. They saw it 
including three principles; reciprocity, altruism, and solidarity.  
Each principle is important to participants. They framed discussions of healthcare in sometimes 
contradictory ways, emphasising transactions on some occasions (the principle of reciprocity) and 
generosity on others (the principle of altruism), and the provision of care based on need, rather than 
citizenship (the principle of solidarity), overall these three themes were always present, and 
participants felt they were necessary features of the social contract. 




2 The social contract in healthcare today 
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Figure 2.1: Public views of key behaviours in the social contract  
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2.1.2 Reciprocity  
There is a large part of the social contract in healthcare which is seen as essentially transactional.  
In this transaction, the public pay through direct taxation which represents what they give to the 
system.  
In terms of what users get, participants expected the NHS to provide evidence-based care, and to 
treat and help the patients who come through the door.  
“People will come in, and are dealt with when they come in, they will be seen when they have their 
appointment time.” London event 1 
Patients are given diagnoses and information about their condition and the chance to discuss it with 
their doctor.  
Participants also felt that part of reciprocity was the public having high expectations of care, wanting 
the most effective treatments possible irrespective of the cost, and treatments that benefit but don’t 
do harm (i.e. side effects).  
“Diseases that have not been eradicated today…Cancer is the biggest one.” Leeds event 1 
 
“I think there will be better medicines available.  Cures for diseases we can’t currently cure.  Hopefully 
cure for cancer at some stage, the common cold.”  Coventry Event 1 
When we came to discussing genomics, participants also expressed high expectations for rapid and 
tangible advances in healthcare; in Chapter 6 we discuss the implications of this and how expectations 
might need to be managed carefully. 
In the reciprocal healthcare relationship, the clinician is trusted to share patient information and data 
only with those who are directly involved in a patient’s care. Participants expected that the standard in 
today’s healthcare was that clinicians would otherwise keep patient information confidential.  
“I just thought NHS medical records would stay in the NHS, with your doctor, because of your 
confidentiality.” Coventry event 1 
In this transactional relationship, participants thought that the Government’s role is to manage and 
deliver healthcare services efficiently, through taxes collected centrally.  
However, the reciprocal relationship is also seen as under strain due to the demand of patients for 
higher quality care, an ageing society, a rise in population levels, problems in mental health, as well as 
in the social care system with its knock-on effect on the health service were all mentioned 
spontaneously. Participants really were worried that the NHS may not be able to fulfil its part of the 
deal going forward. 
“Everybody’s worried.  It seems people are more worried about the NHS than optimistic about the 
future of the NHS.” London event 1 
 
“I think the services need to be joined up.  I’m talking about social care and healthcare.  A lot of the 
time, the amount of waste that goes into healthcare in regards to bed blocking, you’re talking tens of 
millions of pounds per year.” Coventry event 1 
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Participants overall felt the NHS isn’t sufficiently funded by the Government, (even noting that the 
dialogue workshops took place shortly after it was announced that the NHS in England will receive a 
funding increase totalling £20.5 billion in real terms by 2023/24).  
“The lack of funding to me is a political choice.  The UK spends much less of their GDP compared to 
other countries, and that’s a political choice.  Our taxes are relatively low.  If you want a good NHS 
you need to raise taxes.” London event 1 
And, it was clear that unless there is more confidence in the ability of the NHS to deliver core services 
then that will impact support for, and buy-in to, genomics.  
Some participants felt the terms of the reciprocal relationship were already changing, and spoke 
about a greater emphasis on flexibility, and personalisation, where the use of data and technology 
enables services to be delivered more efficiently, and empowers people to make informed choices 
about how they live their lives.   
“Because of that, we might end up with a situation where we have more flexible and more improved 
services that involve outreach, so you don’t have to go to the hospital setting.  The technology will be 
used so you can do some of it remotely and take the pressure off.” Coventry event 1 
As noted in the executive summary, consent is one of four areas of medical practice which the 
Generation Genome report argues needs re-thinking in the world of genomics. The public are clear 
that consent to use data for health research purposes is a core part of the principle of reciprocity, but 
participants in this dialogue took this so much for granted that it was unconsciously accepted, and 
was not spontaneously mentioned. Section 4.1.2 discusses changing expectations of consent.  
In terms of the expectations of users of the service, participants felt their role in the reciprocal social 
contract was to behave well (to not abuse NHS staff), to not waste resources (turn up for an 
appointment) and be appreciative of the care being provided.   This went further than simply 
appreciating your own care, into expressing support for the NHS more widely. 
2.1.3 Altruism  
However, the ‘give and get’ transactional mentality is not the only way that participants conceived of 
the healthcare relationship.  
Participants felt that a working social contract requires people to want to benefit others as well as 
themselves.  Individual behaviours such as blood and organ donation and giving to cancer research 
were mentioned by many.  
“Things like giving blood have gotten better., and they even say whether your unit of blood was used 
in this hospital.” Edinburgh event 2 
(Once explained) participation in health research was seen as an altruistic act. A recurrent theme 
throughout the dialogue was participants’ willingness to support, and participate, in health research, 
once they heard about it; and even if it didn’t deliver direct individual benefits.  
The NHS was seen to carry the legal, and ethical duty of providing healthcare services that are free at 
the point of delivery. It was generally accepted that nobody should be turned away from the NHS, 
regardless of a person having UK citizenship.  
Although stretched resources are a current political flashpoint, and there were a few mentions of 
health tourism, participants overall took the moral stance that it would be wrong to deny care, 
especially emergency care.  
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“It has to remain available.  Whichever way it goes forward, it has to be available on the basis of need 
and not the ability to pay.” Summit 
 
“The good things are quick access, like getting seen straight away in A&E.  The service is good, staff 
have always tried their best with the resources that they have. Coventry event 1 
2.1.4 Solidarity 
Solidarity was the third principle of the social contract. While reciprocity considered the payment of 
taxes as a direct payment for care received, the solidarity attitude also acknowledges that we should 
all contribute to healthcare through progressive taxation.  
In the dialogue this emerged as a strong social norm; participants valued a healthcare system that is 
not based on an ability to pay, and which does not require private health insurance. Spontaneously, 
some expressed willingness to pay more tax, with some calling for a hypothecated tax to ensure the 
NHS can cope with the demands it faces.  
“I can see us drifting towards an Americanised system where it’s going to be attached to insurance.” 
Coventry event 1   
A system based on solidarity, participants thought, involved us all accepting that individual good 
health contributes to the public good, and complying with health instructions (e.g. vaccinations) to 
reduce the public health burden.   
“You are responsible for yourself as an individual.  It’s in your interest to promote your good health.  
I’m not suggesting you wouldn’t be treated.  If you abuse and live a lifestyle that is self-harming, 
you’re a burden on the NHS and everybody else, so it’s down to education and lifestyle.” Summit 
The solidarity elements of healthcare were those which focused on public health; with the aim of 
making people healthier, improving people’s quality of life in old age, and preventing illness, all of 
which were seen as making cost savings for all of us in the longer-term. 
“Preventative medicine rather than curing. I’m thinking about the money it is going to save later on.” 
Edinburgh event 1 
Triage was an implicit part of solidarity; participants wanted services to be directed to where the need 
is greatest.  
“One thing I love about the NHS, the NHS hate postcode lotteries and one of the aims is they can say, 
‘It needs to be the same’.” London event 2 
Clinicians were seen as having a moral and ethical duty to treat everyone equally and with respect – 
the expectation is that they are non-judgemental, making decisions which are based on a person’s 
clinical need.  
2.2 Missing elements: private sector 
While participants were able to clearly articulate their expectations of healthcare, and why they value 
it, there was an overall limited understanding of how the healthcare system works.   
There was an implicit assumption that the system which drives healthcare is run and managed by 
public sector decision makers, who are motivated by the public interest, rather than the private sector, 
which participants think of as always motivated by profit.  
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“Companies don’t do anything for nothing.” Leeds event 1 
Because the healthcare system isn’t sufficiently understood by its users (the dialogue participants), 
there was initial consternation among some about private companies being involved in healthcare.  
Among some this was based on a belief that private sector interests should not be allowed to have 
any involvement in public institutions like the NHS, as ‘private’ was associated with a decline in service 
standards.   
Once explained that the NHS has for many years partnered with commercial companies to ensure the 
NHS can provide services, and equipment (e.g. electrocardiogram) that meet the needs of its users, 
the importance of public-private sector partnerships was acknowledged.  But, there remained an 
unease among many about companies profiteering from people’s vulnerability and poor health, as 
they perceived it.  
2.3 Missing elements: research ecosystem and how research feeds clinical practice 
Participants did not mention researchers spontaneously, (neither based in public nor private sector), 
having little prior knowledge of the role of research in healthcare25.  The dialogue participants were 
largely unaware of the framework of research which underpins and pushes forward medical advances.  
Overall, participants felt that striving for more effective treatments was part of the reciprocal 
responsibility of the healthcare system.  However, this constant improvement to care is, of course, 
only possible if based on a thriving research sector. 
As health research is something which many haven’t considered, few understood the distinction 
between basic and translational research – at best there was a vague appreciation of late stage clinical 
trials – or the cost of innovation.  
“I don’t know what they [pharmaceutical companies] do.  Do they focus on innovation and 
technology? I think it’s unrealistic that the NHS can fund that explicitly.” Summit. 
There was a limited understanding of how research is funded, the range of organisations undertaking 
research, or, of why new medical discoveries will increasingly emerge from collaboration. A few even 
suggested that the NHS should “just go it alone and make medicine itself”.   
That said, there were some individuals (from a higher socio-economic group) who knew more about 
the health research ecosystem, the cost of innovation, and appreciated that commercial companies 
are integral to improvements in clinical care.    
“They are linked.  The research, the universities, hospitals, it’s a whole.  They are all working together.  
They’re the ones who are providing money, investing.  The NHS benefits too.” London event 2 
 
“You can’t paint drug companies as an evil system.  Without the research, there wouldn’t be any 
progress or cures for treatment.  It’s an interdependent system.  It has to go through massive 
amounts of research.”  Summit 
Finally, because clinical research was seen as separate from research practice, participants also didn’t 
appreciate how clinicians and researchers are bound by different codes of practice and ethics, which 
                                                     
25 This lack of knowledge about the framework of research which underpins healthcare, and the role of the private sector in healthcare, 
chimes with findings from similar dialogues we have conducted such as the public dialogue for AMS on public views of data-driven 
technologies; and the public dialogue for the HRA/HTA on consent to medical research 
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means the nuance of understanding the clinical / research differences and overlaps in the context of 
genomics was difficult for participants to grasp. We discuss this issue further in the next chapter.  
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3.1 Overall views of genomics and the participants’ journey 
In order to put into context public views of what genomics will add to the social contract, we first 
need to set out the public’s starting points, and how their views were shaped during the hours they 
spent discussing genomics. Participants formed their views based on experts’ remarks, prompts from 
the facilitators with very detailed discussion guides (see annex), and stimulus presentations from a 
range of experts. Across the events participants gained views from other participants, bringing up 
issues, sharing their opinions, and asking the experts for clarification and having long and in-depth 
conversations that the rest of the group could hear. Ipsos MORI have drawn our conclusions on the 
different participant journeys that each of them took. This is summarised in section 3.11 below.  
3.1.1 Limited understanding of genomics but lots of optimism once explained 
We know that the public have a limited understanding of genomics. Indeed polling we did for 
Genomics England found that two-thirds of the public know very little or nothing at all about 
genomics26. In the dialogue discussions almost nobody had heard of a ‘genome’ or ‘genomics’, which 
chimes with empirical research commissioned by Genomics England that showed 85 per cent of 
British adults had not heard of the word ‘genomics’ before27.  
A few participants in this study had however bought a genetic testing kit from 23andMe and 
Ancestry.Com; and in section 7.1 we suggest that a better understanding of why people are willing to 
share genetic data in such a context could be useful insight for decision-makers seeking to encourage 
genomic donation.  
There was good recognition of the term ‘genes’, and lots of interest in how they influence a person’s 
health relative to a person’s diet, lifestyle and area where they live; and, (once explained) some felt 
that genetic information was an opportunity to “nudge” people to make better choices, that improves 
public health.   
As just over half of people (53 per cent) think that the UK Government does too little to help people 
live healthy lives28, genomics seems to present an opportunity for the UK Government to be seen as 
enabling more healthy lifestyles.  
Common genetic disorders like Down’s syndrome and cystic fibrosis were well known, but conditions 
affecting population groups were less familiar e.g. sickle cell disease.  
The accuracy and reliability of genomic analysis was a worry, particularly to the dialogue participants 
from a Black and Minority Ethnic (BME) background, given historically poor access to health services 
and underrepresentation in clinical trials. Therefore, the public expect that researchers and clinicians 
                                                     
26 National representative polling Ipsos MORI did for Genomics England in May 2018 found that two-thirds of the public know not a lot or 
nothing at all about genomics / genomic medicine. The full report and topline findings can be accessed at the following link: 
https://www.ipsos.com/ipsos-mori/en-uk/public-awareness-and-knowledge-genomics-genomic-medicines-low   
27 Middleton A. Socialising the genome: making genomics resonate. F1000Research 2018, 7:149 (slides). Detailed findings can be accessed at 
the following link: https://doi.org/10.7490/f1000research.1115249.1  
28 https://www.ipsos.com/ipsos-mori/en-uk/public-and-nhs-70-years-together  
3 Public views of what genomics will add 
to the social contract  
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must inform patients about the boundaries of the genetic test such as its familial implications, and its 
uncertainties such as its probabilistic nature, and do this in an intelligible way.  
Also a particular worry for BME participants, as well as other participants, was that a genomics data 
database or ‘library’ as experts in some of the dialogue workshops described the idea of a genomic 
database, creates a possibility for genomic data to be used by the authorities to create a ‘surveillance 
society’. All participants said emphatically that this would fracture trust in data donation, and was 
considered a red line. Section 4.3 further discusses participants’ red lines.  
Overall, however, in our dialogue there was a very positive response to genomics. Special benefits 
were seen for cancer, rare and ultra-rare diseases, long term life limiting illness, the lives of children, 
and improvement to patient choice with more knowledge about individual predispositions.  
“The whole thing makes me feel quite optimistic.  Something like dementia, taking strides to 
something like that is worthwhile.  Joined up thinking and working together is a great thing.” Leeds 
event 1 
However, the public have high (somewhat unrealistic) expectations, with many participants envisaging 
a near-term future with new treatments and personalisation of care, and significant cost savings for 
the NHS. 
“The amount of money that will be saved for the NHS by the prevention of these conditions, rather 
than treatment, has to be beneficial.” Summit 
As such, in the short term public expectations will need to be carefully managed (see Chapter 6); the 
information the public will need in the first few years after launch is likely to be different from 
information needs ten years into the programme.  Changes in the wider world may also condition 
expectations (an example is the recent public debate on a gene editing ban following evidence of 
human gene editing trials taking place in China.) 
 
After hours discussing genomics, almost all were relaxed about their health and genomic data being 
used in health research. This support though is conditional on consent (section 4), the use of de-
identified data as routine and red lines being respected (section 5), robust risk assessment and 
safeguards being implemented and maintained by policy makers (section 7), and of course, clinical 
impact.   
“That’s what changed with me from the first session.  When we were told your data is shared, I was 
like, ‘Oh my god.’  As the discussion went on, I realised the importance of sharing data, it shows up 
trends.” Coventry event 2 
The views of participants in the Edinburgh workshop29 
The views expressed by participants in the Edinburgh workshop were effectively the same as those 
in the workshops in England. This chimes with what we know already about attitudes to sharing 
patient data for health research which is that a nexus of educational attainment, socio-economic 
group and digital literacy, rather than geography, are more influential in shaping people’s views.30   
                                                     
29 As agreed with Genomics England and the Scottish Genome Partnership we have analysed the Edinburgh workshop results together with 
the results from the dialogue workshops conducted in England. The report contains quotes from all of the events.  
30 Ipsos MORI (2016) Public attitudes to commercial access to health data pp. 85 https://wellcome.ac.uk/sites/default/files/public-attitudes-
to-commercial-access-to-health-data-wellcome-mar16.pdf  
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Overall, the Edinburgh participants were relaxed about developing genomic testing further in NHS 
Scotland and expected research findings to lead to new ways of working and improvements in care.  
3.1.2 Issues in genomics were initially seen as similar to others in healthcare   
In general, many of the issues around genomics initially raised by participants are similar to others in 
healthcare, and although the language and specifics may be new, many of the ethical and practical 
issues are seen as the same. These include:  
• Doctor taking responsibility – the clinician is still seen as responsible for providing the best 
care possible.  However, the dialogue participants were worried that stretched resources in 
the NHS will mean that the system won’t be able to cope, and the benefits of genomics won’t 
be equally redistributed in the longer term.  
• Evidence-based decision-making – participants want doctors and clinicians to be empowered 
to make their own choices, and are worried about doctors becoming ‘bogged down’ in 
administrative justification for their decisions. Moreover, participants expect that decisions 
made by clinicians are informed by the best available scientific evidence, and it was felt that 
genomics would enable better decision making, and access to new treatments.  
• Incidental findings – participants weighed up a number of factors when discussing if they 
would want to be told about incidental findings which are not derived from genetic analysis: a 
positive prognosis of the ‘other’ condition, a person’s emotional resilience, and support to 
deal with the consequence of knowing the result. These factors were the same in genomics, 
although once they reflected on familial implications, this added a complicated ethical 
dimension to their decision-making (see section 4.1.1). 
3.2 Public views of what genomics will add to the social contract  
3.2.1 The same core principles, but new intersections between them  
The rest of this page is a brief overview of the key points which are presented in the remainder of 
Section 3.  
By the end of the dialogue, participants had discussed the implications of genomics for the social 
contract.  Overall, in a genomics-driven healthcare of the future, they felt the principles of reciprocity, 
altruism and solidarity would need to remain core to the social contract, and require largely the same 
behaviours of all the actors as they do at the moment.   
For example, clinicians are expected to treat all equally and with respect, and patients turn up to 
appointments and appreciate value of care.  
However, the new science of genomics means that the three elements might intersect in new ways - 
leading to new expectations of behaviours of all actors in the system.  
Reciprocity intersects with altruism: Genomics requires donation of data from individuals. This blurs 
the line between reciprocity and altruism. The public in the dialogue saw giving their data as an 
altruistic act - but also expected benefits would probably accrue to their families and descendants.    
Similarly, reciprocity and solidarity also blur. Genomics can use patient data in research and clinical 
care at the same time, creating a feedback loop between both to increase possible learning.  
Participants felt that this research/clinical blurring brought the ideas of reciprocity and solidarity closer 
together. 
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Solidarity and altruism also become more closely connected. In the future, if large genomic dataset(s) 
exist, and can potentially be accessed by new actors, (such as commercial companies) social solidarity 
will be affected by the altruistic acts of individual donors. 
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Figure 3.1: Public views of what genomics will add to the social contract  
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3.2.2 Reciprocity links with altruism  
Participants quickly grasped that genomics requires donation of data from individuals, and when 
experts described how they hope genomics will impact healthcare, they saw giving their data as an 
altruistic act. This blurs the line between reciprocity and altruism.  
“It's part of your social contract to make your information available.  Your genomic information might 
hold the key to a breakthrough in research.” Edinburgh event 2 
Initially it was thought that when people give their genomic data, they will get more back than they 
do currently, but during discussion they came to realise that benefits would probably accrue to their 
families and descendants.    
“It could mean the gift you pass on to your family.  If there are any problems in the future which are 
health-related, they could be helped.” Summit   
Therefore participants thought there would be an increased expectation that the public would donate 
data, although it was clear that data donation should not be mandatory. 
“I think genomics is brilliant. Collecting the data for the next generation, they need it. That’s a 
wonderful thing to be able to do that.” Coventry event 1 
Participants saw the genomic medicine service as altruistic, in that they felt the learning and insight 
derived from those who participate in the service should be used in the treatment of other cancer and 
rare disease patients who are offered whole genome sequencing or genetic testing, in order to see 
how their situation compares.  
Participants were happy in principle to support those who chose not to donate data, but who would 
still be treated; and they felt that nobody should be forced to give their genomic data, instead people 
need educating about the benefits of altruism (genomic donation), and the benefits of being 
altruistic. 
“It’s about, so far, one of the biggest things coming out of this is sharing the data, so if they get the 
foundations right, once you’ve gained the trust, it’s about educating the public so they tick the box to 
share.” Coventry event 2 
This was because they could recognise, albeit after hours of discussion, that genomic medicine relates 
to us all – comparing all our genomes must be seen to be done in an altruistic way, with a concern for 
the wellbeing of all. This is seen by participants as particularly intrinsic to genomics, making altruism 
even more important than it has been in the past. 
“It’s an investment into the future.  My grandchildren might benefit.” Coventry event 2 
 
“You have to keep yourself informed, so that it’s an everyday thing that we have a conversation on.  
Knowledge is power.  We’re tuned into the message of having a flu jab every year.  We need a 
message as strong as that, so that we all know what’s happening.” Coventry event 2 
As well as feeling altruistically that genomics is a human-scale project and all in society can ultimately 
benefit from its advances, there was a feeling that treatments derived from genomics should benefit 
those contributing to the system, and people in the UK especially. 
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Participants thought therefore that government and healthcare policy makers would need to create a 
roadmap for genomics where the status of data donors is made clear, and any rewards for them 
carefully worked out, to balance the interests of altruism and reciprocity. 
3.2.3 Solidarity links with reciprocity 
Solidarity in genomics is predicated on an assumption of collective action; that all agree to take part 
in, to bring about improvements in clinical care and health research.  
Genomics can use patient data in research and clinical care at the same time, creating a feedback 
loop between both to increase possible learning. Participants felt that this research/clinical blurring 
brought the ideas of reciprocity and solidarity closer together. This gives researchers and clinicians 
new duties of care.  
A changing relationship between clinicians and patients is already apparent as a result of uptake in 
new types of data gathering (e.g. wearables), and the use of technology in delivering services (e.g. 
virtual appointments).  
But, given the way research can feed clinical treatment and vice versa, participants were clear that 
researchers have new responsibilities in genomics.  
First, participants felt that both clinicians and researchers in a genomics future would be responsible 
for ensuring that patients and families are informed about the progress of research. 
Second, both researchers and clinicians should also focus on ensuring the translational benefits of 
research to care, to benefit all of society, as quickly as possible.  
“Potentially faster diagnosis of problems.  That would lead onto much quicker decisions about what 
treatments are best suited to that particular individual rather than a spectrum of stuff.” Leeds event 2 
Third, both researchers and clinicians should communicate, what they are doing with genomic data, 
and the link between their work and eventual discoveries with clinical impact; so the public can know 
their collective action is worthwhile and having impact. 
Finally, the public think that patients are in a unique position to help shape the service that takes 
shape around them – and therefore clinicians (and researchers) should engage and take their views 
on board as much as possible.  
3.2.4 Solidarity links with altruism 
In the future, if large genomic datasets exist, and can potentially be accessed by new actors (such as 
commercial companies), participants felt social solidarity will be affected by the altruistic acts of 
individual donors.   
“Genetics feels like an individual thing, but it’s very social.  The results always implicate other people.”  
Coventry event 2 
Dialogue participants felt that policy makers should take a long-term view and design a system which 
prevents dystopian social outcomes in the future.  
Participants emphatically did not want their donation of genomic data used to create a stratified 
society which disenfranchises vulnerable members.  (e.g. genomic datasets being heavily used in 
insurance, marketing, etc – which are discussed in Chapter 5 below).  
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There would be a new role for industry in bringing the benefits of genomics to society; but either 
voluntary or external regulation will be needed. Again, participants did not want to see the altruistic 
data donations of individuals used to enable private sector profiteering (discussed in Chapter 5).  
Ultimately, the public want policy makers to design a system that prevents these things from 
happening in practice. Rational ignorance31 means participants are willing to defer its design to the 
NHS and experts with no vested interests (such as a panel of “lay-experts” e.g. 100,000 Genomes 
Project Participant Panel32). Section 7 discusses what the governance framework of this system should 
look like.   
                                                     
31 It's impossible to know everything. Some degree of ignorance is inevitable, and we all must personally decide what is worth knowing and 
understanding. Rational ignorance helps each of us decide what information would be most useful. Rational ignorance means intentionally 
choosing to remain uninformed on a topic because the cost of acquiring the information is greater than the estimated potential benefits. 
https://study.com/academy/lesson/rational-ignorance-definition-effect.html 
32 https://www.genomicsengland.co.uk/participant-panel/  
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4.1 Changed expectations around data donation  
As well as the additions to the social contract, participants also felt there would be one change to the 
social contract; genomics changes the expectation that clinicians will only share data with those 
involved directly in patient care.    
4.1.1 Changed expectations of confidentiality  
Registered medical professionals have both a (legal) duty of care and a (legal) duty of confidentiality 
to their patients – breaching either of which can be grounds for de-registration. This is recognised to 
be the fundamental basis of trust in healthcare, and has been for longer than the NHS has existed. 
The fact that a genetic result has implications for an individual patient as well as their family members 
introduced the dialogue participants to some complicated ethical questions.  
These questions were introduced using hypothetical family tree scenarios (see annex B). For example, 
participants were told about a woman who finds out she has the BRCA1 gene alteration after having 
her genome sequenced, thus increasing her risk of developing breast cancer.  
They were also told that the woman has a twin sister, but wants to keep the test result between 
herself and her clinician. The main question was: does the twin sister have a right to know about her 
sister’s gene alteration given the possible implications for the sister’s health; and if so, how should she 
be told?   
The resultant discussions identified some barriers to sharing genetic information. Individual rights 
were seen as being in tension with family rights and views could become very polarised and split.  
Spontaneously most participants didn’t want data used beyond a person’s care, because 
confidentiality has always been part of healthcare.  
“If people breach their own confidentiality by their own means, they need to take responsibility.  The 
NHS must keep it secret.  If that woman doesn't want to be tested, that needs to be kept secret.  If 
her family subsequently find out from her, that's her responsibility.” Edinburgh event 2 
But after discussing the implications of the genetic test result based on the hypothetical family tree-
scenario, most did not see patient confidentiality as axiomatic to the social contract in the context of 
genomics involving data with family implications. 
“If the parent’s got a potentially serious disease and it’s potentially through [knowledge from a test 
their child’s had], the doctor has a duty to tell his parents.” London event 2 
They also felt that there was a moral obligation for patients to find out what they can about their own 
health and, with guidance from genomic counsellors and clinicians pass on as much information to 
benefit their families rather than harming them by omission by not telling them critical information.  
But, after hearing genetic clinicians recount stories of how these implications can play out in their 
work, some cooled on this idea because they thought it was too idealistic. They felt that some 
patients and families of patients motivated in a petty or personal way would withhold information of 
critical importance.  
4 What the public think will change in the 
social contract 
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By the end of the discussion, it was felt that there should be an assumption that patients and their 
blood relatives will be informed of all medically relevant information.  
“In this scenario the GP (of one patient) should talk to the GP of the relative.” Edinburgh event 2 
Participants wanted to empower clinicians to make the final decisions on disclosing information; but 
at the same time were concerned not to add any administrative burden on clinicians from a medico-
legal perspective. 
In order to facilitate this, clinicians need reassurance from policy makers, and from the medical 
profession so they feel confident to make such decisions, and potentially to develop a transparent 
framework for how they exercise their expert judgement, so that individuals are not left vulnerable 
and open to criticism.   
“Legislation needs to be there to protect the practitioner and the public.  What would that look like?  
They can sort that in the Houses of Parliament.” Coventry event 2 
Finally, there was a feeling among some (who tended to be participants from a high social economic 
grade) that genomics and the new era of data-driven technology in healthcare will usher in a social 
contract characterised by clinicians who understand, actively manage, and communicate risks and 
tensions to patients.   
4.1.2 Changing expectations of consent  
There is a significant amount of public opinion research on consent for use and access of patient in 
health research. Indeed, our recent dialogue for HRA/HTA33 tested the public’s comprehension and 
acceptability of broad consent, so-called hybrid consent (100,000 Genomes Project consent form), 
and dynamic consent which allows participants to adapt their consent preferences.  
The focus of this study was to uncover the nuances of consent in the context of genomic data, rather 
than repeat the consistent and clear research that already exists.   
Spontaneously participants in this dialogue wanted assurances that consent was built into the process 
of genomics. 
“You’ve got to give your consent, a right to refuse.” London event 2 
Initially, the dialogue participants thought that consent should make it explicitly clear who will have 
access to their data and how it would be used, but after it was explained it is not always possible to 
be so clear upfront, there was a pragmatic agreement that prior consent may no longer be possible 
for all uses.   
And so participants accepted that there may be un-knowable outcomes from genomic research, and 
as a result they are willing to let go of knowing precisely which research projects will use their data, 
for the sake of personal and social benefit.  
“There should be an opt in system.  If I had the option today, I would be diving right in there.” 
Edinburgh event 2 
But, they were very clear that doesn’t mean their willingness to participate in research is 
unconditional, as consent must be based on research which has been ethically-approved and is for 
the public good.  
                                                     
33 https://www.hra.nhs.uk/documents/1570/Consent_to_use_human_tissue_and_linked_health_data_in_health_research_FINAL.pdf  
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“As a nation, because genomics is a good, everyone should be opted into it.  If you want to be opted 
out, you can.” Coventry event 1 
The focus of this dialogue was not to define what constitutes “ethically-approved”, and rational 
ignorance means participants are willing to defer safeguards and governance to both the NHS and 
experts who have no vested interest in genomic research.  
 
The dialogue participants were also clear that the public should have their dissent to their genomic 
data being used in health research recognised34, and have a choice about those who have access to 
the data (e.g. commercial interests). Almost nobody felt they would opt out, as they could accept that 
an increased risk to privacy is worth the diagnoses and personalised medicine they might receive.  
4.1.3 A new need to inform and educate the public about what has changed 
Participants felt both clinicians and researchers should be equipped with “genomic literacy” to 
support the informational, emotional and practical needs of patients and data donors; giving more 
information and support than has been necessary in the past when communicating with research 
participants.    
Participants suggested that clinicians in particular should seek out genomic literacy opportunities so 
they feel confident discussing the uncertainty of diagnosis / treatment, and are able to convey 
information derived from genomic analysis to lay people. 
 
“If I were told by a genetics counsellor that I had a condition that affects my family, I would have no 
children.” Coventry event 2 
The dialogue reveals areas where communication skills might be important. There was limited 
understanding of the nature of a genetic test result, and even after information from experts, some 
participants spoke about it in terms of a binary yes / no answer i.e. certainty. This will need to be 
explained carefully to patients and data donors in future.  
 
Once the nature of the test result was explained, views about feedback were often based on 
perceptions of certainty of diagnosis, risk of harm, likelihood of getting it, or time between the test 
result and on onset of symptoms.  
 
When these nuances were discussed, participants wanted Government to ensure the NHS has the 
resource it needs to deliver excellence in communication throughout the “genomics pathway”: 
genomics counsellor, clinician, researcher.  
 
“The most important thing is to ensure that the relevant structures are in place to make it work.  
We’re talking about people like counsellors, otherwise it won’t work.  Lots of projects have lots of 
money put into them and 8 years down the line, the plug gets pulled.” Coventry event 2   
 
“These people must be specifically trained and that will cost money and time.  It is a great thing, but 
huge.” Summit  
                                                     
34 The national data opt-out (NDOP) was introduced on 25 May 2018, enabling patients to opt out from the use of their data for research or 
planning purposes, in line with the recommendations of the National Data Guardian in her Review of Data Security, Consent and Opt-Outs. 
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It was acknowledged that informing patients about the meaning of different consent options and the 
implications of different test results were both very important.  
 
Participants were surprised and reassured when it was explained that genomic counsellors can spend 
up to forty minutes discussing such things, as they had envisaged an appointment time of around ten 
minutes.     
 
But they were soon worried that the NHS would not have sufficient numbers of genomic counsellors 
to meet demand. Assurances around workforce planning and training more genomic counsellors did 
not convince. They believed these things will take a long time to realise, and in the meantime, they 
believed there would be long waiting times and geographically patchy services. As such, policy 
makers need to make it clear how the system is able to cope with the broader roll out of genomic 
medicine, and specifically ensure there are sufficient numbers of genomic counsellors, and clinicians 
that are literate in genomics.   
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Figure 4.1: Public views of what genomics will add to the social contract, and what will change  
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5.1 Views of genomic data and access  
Reactions to the idea of genomic data being different were less about inherent difference – it was 
often seen as on a par with other forms of health data – and more about uses of genomic data, 
particularly outside of healthcare, and the fact that it has familial implications, as discussed in 4.1.1 
above. 
 
There was low understanding of the concepts of data aggregation, anonymisation vs de-identified 
and data linkage; and no spontaneous sense of ‘mutuality’ of data – the fact we can learn more about 
all of us by looking at the data together. However, when this idea was introduced in the context of 
healthcare and genomics, people supported it. 
 
Participants’ attitudes to access of genomic data were the same as identified in previous research:  in 
general, the wider public is happy for the NHS to use people’s health data35, but there is less support 
for commercial companies having access, even for research36. But overall the public think it is 
acceptable to gather data, and use it outside the NHS, if the usage passes four key tests identified in 
our Wellcome study on commercial access to healthcare data37.  
 
 
                                                     
35 Ipsos MORI / Deloitte LLP (2017) The State of the State 2017-18: Austerity, government spending, social care and data. Full survey results 
can be accessed at the following link: https://www.slideshare.net/IpsosMORI/the-state-of-the-state-20172018   
36 Ipsos MORI / The Health Foundation (2018) NHS at 70: public perceptions. Full survey results can be accessed at the following link: 
https://www.ipsos.com/sites/default/files/2018-07/public-perceptions-of-the-nhs.pdf   
37 Ipsos MORI / Wellcome Trust public attitudes to commercial access to health data 2016 https://wellcome.ac.uk/sites/default/files/public-
attitudes-to-commercial-access-to-health-data-wellcome-mar16.pdf  
5 Public views of genomic data: access 
and use outside of healthcare  
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Participants in this dialogue expressed their views in accordance with these priorities, in comments 
such as the below:- 
 “If it benefits people, I don’t care who the NHS are sharing my data with as long as it’s not Facebook 
and Google.” London event 1 
Sharing genomic data (with researchers) internationally was an initial red line, as participants assumed 
standards of data security and governance are not as high as in the UK. Views quickly shifted to 
acceptance after it was explained that the NHS has put in place all the necessary (statutory) 
protections, because participants support the idea that genomics will be more quickly realised by 
sharing genomic information with a community of genomic experts.  
“Bringing it together anonymously would advance knowledge in certain diseases…Why work 
separately when you could have the great scientists of the world working collectively?”  Coventry 
event 1 
5.2 Genomic data use outside of healthcare: insurance 
When applying for insurance a person has to disclose any symptoms they experience or any 
diagnoses, screening, or treatments they receive, if this information is requested on the application 
form. In some cases, genomic or genetic testing can discover a predisposition to disease. 
The dialogue participants were asked to consider how they felt about sharing a genetic test result if 
they were asked to disclose this information.  
It is worth briefly setting out the context in which reactions to this question are formed. The insurance 
industry has some trust issues: In 2017, only around a quarter of British adults said they trusted the 
industry38.  
The use of genetic test results in insurance was initially a big shock. There was lots of high feeling, and 
some felt so strongly about sharing data with insurers that they said they would not donate their 
genomic data.   
“I’d be less inclined to have my genome sequenced if I knew it would affect my insurance.” Coventry 
event 2 
There was almost no recognition of mutuality: the key principle of commercial insurance, whereby 
individuals pay according to the best estimate of the risk that they bring with them; or the uberrima 
fides principle, or utmost good faith, where each side declares all it knows about the risk39. The 
insurance industry was associated with ‘sharp practices’ when it comes to honouring insurance claims.  
The starting point was often that insurers should not have access to additional health data. In terms 
of genomic data, it was felt that it would enable insurance companies to extract maximum premiums 
from people, punish people for poor health, and make insurance unaffordable to those who need it 
most.   
There was almost no recognition of the importance of pricing risk accurately, and that this is good for 
the health of society, as well as commercial sustainability.  
                                                     
38 Ipsos Global Trends Survey, 2017. Full survey results can be accessed at the following link: https://www.ipsosglobaltrends.com/  
39 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1691992/  
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And, when it was suggested that premiums might go down if a test result showed a low health risk, 
the dialogue participants just didn’t believe it would happen.  
“It’s like they want to know whether you’re a good investment or not, in a sick twisted way.  I don’t 
know.  I’m not sure.” London event 2 
Participants were told that a new code of practice for insurers had just been issued40. It was explained 
that it is not a binding law but a code to which the industry signs up that is taken very seriously by the 
companies involved i.e. the members of the Association of British Insurers.  
It was hard for participants in this dialogue to grasp the voluntary nature of the code of conduct, 
which chimes with how participants in our HRT/HTA dialogue on consent felt about the moratorium 
for sharing genomic data with the industry41. In both dialogues, participants were worried that it 
would be difficult to enforce, and hard for consumers to hold companies to account.  
Figure 5.1: dialogue stimulus of HMG/ABI code of practice for insurers  
 
And, there was consternation about the parameters of the code (see figure 5.1, and figure 5.2 
overleaf). The inclusion of Huntington’s disease – the only genetic condition which insurers are 
permitted to ask applicants to disclose – was even questioned, unless it has been substantiated that 
the applicant has inherited the defective gene.   
                                                     
40 A voluntary code of practice agreed between HM Government and the Association of British Insurers on the role of genetic testing in 
insurance was published by HM Government and Association of British Insurance in October 2018. It can be accessed at the following link: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/751230/code-on-genetic-testing-and-
insurance.pdf  
41 https://www.hra.nhs.uk/documents/1570/Consent_to_use_human_tissue_and_linked_health_data_in_health_research_FINAL.pdf  
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Figure 5.2: dialogue stimulus of HMG/ABI code of practice for insurers  
 
“Some diseases affect certain groups.  Breast cancer affects women more.  You’re going to start 
discriminating against population groups.” London event 2 
Ultimately, participants thought the best they could hope for was that policy makers would carefully 
monitor compliance with the code, because they were resigned to insurance companies adding more 
conditions each time the code was reviewed.   
“What’s stopping the insurance companies when they get their foot in the door, not making it wider?  
They could lower the life insurance amount and make more illnesses available.” Coventry event 2 
5.3 Genomic data use outside of healthcare: the public’s red lines  
Assurances around the de-identified nature of the data meant participants are less concerned about 
personal harms.  
 
However, participants are concerned about broader societal harms, and they identified some clear red 
lines and boundaries when it comes to how far genomic data and information derived from genetic 
analysis should be used outside clinical care and health research, as shown in figure 5.3.  
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Figure 5.3: Public views of what genomics will add to the social contract, and what will change… and red lines  
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5.3.2 Genetic engineering  
Participants were concerned about the possible unintended consequences arising from the field of 
genetics (rather than an NHS Genomic Medicine Service); in the extreme, enhancing human 
capabilities, and eugenics, were mentioned.    
“Another bad point is that we might be becoming too clever with things like genetic engineering. It’s 
an ethical problem.” Edinburgh event 2 
Genetically edited babies was seen as the natural next step, and assurances from experts that “it 
[gene editing] just won’t happen in the GMS” were insufficient, as there was a feeling this would 
happen by ‘accident’, rather by design.  
“A ‘must not do’ is genetically modifying babies in the future.  Designer babies.” London event 2   
When experts explained the difference between genetic modification where there is a gene known to 
cause a debilitating illness (e.g. Huntington’s disease) and changing a feature of a child (e.g. gender, 
eye colour, hair colour), almost all supported the idea of improving the wellness of a child by 
modifying their genetic make-up.   
A few, however, in particular participants whose child has a genetic condition such as Down’s 
syndrome saw advances in genomics leading to more aborted pregnancies, and more prejudice and 
discrimination for people with a genetic condition (e.g. Turner Syndrome42) than there is in today’s 
society. Most though, when discussing the fact that fetal screening test for Down’s is currently 
available, concluded the idea of a more accurate prediction would benefit some parents.  
5.3.3 Surveillance society   
There was real concern that collecting genomic data creates a possibility for it to be used to monitor 
and track citizens, either by corporate interests (e.g. insurance) or by the state (e.g. crime and justice 
and taxation).  
“It should stay within the NHS.  It shouldn’t be used for things like ancestry.com where they were 
used by criminal services.  It’s crossing the boundary of privacy.  It should be kept in the research field 
definitely.” Edinburgh event 2 
The idea of a repository of DNA data was spontaneously associated with a perception of institutional 
racism, racial bias in stop and search practices, and the so-called hostile environment immigration 
policy. Although this was a clear red line, there was a sense of fatalism that the day would come when 
genomic data would be used to monitor and, discriminate against minority and disenfranchised 
groups in society.  
“Not sharing with the police either.  If you’ve got my DNA, you don’t have the rights to share that 
with the police.” London event 2 
 
“They’ll be picking which country to deport you back to which you have no link to whatsoever. That’s 
my worry.” London event 2 
 
                                                     
42 https://www.nhs.uk/conditions/turner-syndrome/ 
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It was felt that insurance companies should not be permitted to use genomics tests for predictive 
tests. While there was interest in the accuracy of prediction in healthcare, in insurance it was 
considered a red line as participants believed that analysis would be used to identify people who are 
likely to have high personal insurance premiums, and as a result reduce access to much needed 
protection.  
5.3.4 Administrative and political uses  
Although nobody made an explicit connection with combining genomic data and administrative43 
data, there was a general feeling that more data is being collected all the time which has the potential 
to be used in ways which people did not consent to or would not vote for: cutting choice, reducing 
access to services such as welfare, and a sense of control of UK citizens were all mentioned as clear 
red lines.  
5.3.5 Targeted marketing  
Genomic data is seen as potentially very valuable to marketers, and participants were very clear that 
data should not be used for marketing or other areas which enable profiteering, especially by 
international corporates.   
There was a feeling that pharmaceutical companies and insurance companies would link genomic 
data with other data outside healthcare, in order to target individuals who are more susceptible to 
these approaches due to their vulnerability (e.g. health condition/illness).   
“I’d be worried about drug companies finding out you have certain illnesses and then they target you 
for testing and certain medications.  Say my data was known and I was shown to get an illness, then 
I’d be targeted by drug companies for research. I might not want to address my illness, I might not 
want to think about it, rather than being targeted and reminded.  It affects your mental health.”  
Coventry event 2 
 
“Once they’ve [insurance companies] got that information, they can use that for their marketing.  




                                                     
43 Administrative data collections are built up by government departments and agencies during their day-to-day activities. They routinely 
gather information, when registering people or carrying out transactions, or for record keeping – usually when delivering a service. Such 
data can include: social security payment records; educational attainment records; health records, court records; and tax records.  
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6.1 Genomics communication context  
Raising the public’s awareness of genomics is already a priority for policy makers. Just a few examples 
are: the Department for Health and Social Care, and its partners NHS England and NHS Scotland 
announcing the achievement of sequencing 100,000 genomes44, the UK Government announcing an 
ambition to analyse five million genomes in the UK over the next five years, plus the publicity around 
DNA testing for children with cancer in NHS England.45   
Alongside these efforts, academics, social scientists and science communicators are involved in public 
engagement projects which seek to raise public awareness of genomics, as well as build support for it. 
For example, the Socialising the Genome46 initiative funded by Wellcome and Genomics England 
looks at what sort of narratives and metaphors raise awareness and seeks to encourage more people 
to talk about genomics47.  
However, this study (including the literature review) and empirical evidence from Ipsos MORI48, shows 
that a lot more work is needed to raise public awareness, and understanding, of genomics.   
 
Before setting out how this can be achieved, it is worth briefly considering the context in which 
genomics is happening. Now is a risky time for data usage. Ipsos’s global survey for the World 
Economic Forum found widespread distrust on personal data usage by companies and governments, 
and as shown in the graphic below, most in society don’t know what data organisations and 
companies hold about them or what they are doing with it49.  
                                                     
44 To deliver the 100,000 Genomes Project, NHS England established 13 NHS Genomic Medicine Centres (NHS GMCs) responsible for 
recruiting and consenting patients, providing samples from both blood and cancer tissue and the clinical information for analysis; validating 
results; and working with patients and clinical staff to broaden the use of genomics across clinical specialities.    
45 https://www.bbc.co.uk/news/health-46777387  
46 https://www.genomicsengland.co.uk/socialising-the-genome/  
47 A short preliminary overview of some of the findings can be accessed at the following link: 
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31011-5/fulltext 
48  National representative polling Ipsos MORI conducted for Genomics England in May 2018 found that two-thirds of the public know not a 
lot or nothing at all about genomics / genomic medicine. The full report and topline findings can be accessed at the following link: 
https://www.ipsos.com/ipsos-mori/en-uk/public-awareness-and-knowledge-genomics-genomic-medicines-low  
49 https://www.ipsos.com/ipsos-mori/en-uk/global-survey-reveals-widespread-distrust-personal-data-usage-companies-and-governments  
 
6 Communicating genomics 
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At the same time, the UK faces some significant challenges: inequality and poverty, an ageing society, 
and the NHS remains the public’s biggest worry after Brexit.50 As such, there is a lot of ‘background 
noise’ that genomics messaging will need to cut through.  
In the remainder of this Section we offer our ideas on how best to communicate genomics and the 
broader roll out of genomic medicine. They are based on the explicit views of participants in this 
dialogue, as well as our analysis of the kinds of messages and phraseology that resonated, plus other 
relevant studies which have looked at ways to inform the public about sharing their health data.  
6.2 Genomics framed as a collective endeavour  
Realising the potential of genomics will require a critical mass of UK citizens supporting it to the 
extent they are willing to participate – while this is a longer-term aim, creating and implementing a 
genomics narrative should be an immediate priority – the dialogue participants were clear that policy 
makers and the NHS have a responsibility to do more to educate people about genomics.  
 
The Socialising the Genome initiative has stated that actors who work in genomics have different ways 
of talking about it, so there is also a need for a shared narrative expressed in intelligible language 
which is used by all actors in genomics.  
The dialogue participants were clear that the NHS will need to manage public expectations of 
genomics in the NHS. Therefore, the narrative will need careful framing, because, if the benefits of 
genomics are over-hyped, or the uncertainties downplayed, there is a risk of fracturing the public’s 
trust in genomics, and health research more generally.  
 
“You make a conversation about it.  It becomes a part of your consciousness.  If it just gets 
rolled out, people aren’t going to be comfortable with it.” Summit  
We suggest that communications should convey the idea that genomics is an ambitious, ground-
breaking programme of activities that will:  
                                                     
50 https://www.ipsos.com/ipsos-mori/en-uk/issues-index-august-2018-public-concern-about-eu-and-brexit-remains-historically-high-levels  
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• re-define what best care is: for example genomics is moving away from “one size fits all” 
treatments to patient care tailored to their unique genetic make-up  
• deliver new medical discoveries 
• but also change healthcare in ways which cannot be predicted with certainty. 
 
This framing will resonate with the dialogue participants’ optimism in genomics, while adding a 
degree of realism that it’s still very early stage and lots of learning and insight still awaits.   
“I think being transparent as well, like not ignoring potential risks and making people really excited 
about the benefits.” London event 2 
The participants from the 100,000 Genomes Project who engaged with dialogue participants 
introduced a sense of realism as to what genomics is able to deliver, and helped the public engage 
with the idea of uncertainty in genomics. As such, we suggest these personal contacts could be useful 
in wider communications. Examples could also help manage public expectations – for instance, talking 
about cystic fibrosis, which was one of the first conditions to have its genomic component properly 
understood and yet no genomic treatment has arrived in the NHS in over 30 years. 
 
The genomics narrative should not be confused with a service like blood or organ donation, which 
was a key misunderstanding in the dialogue discussions.  Instead, communicating the idea of a 
“national moonshot” or shared endeavour may work to link genomics to a wider UK programme of 
innovation in which we are all involved.  
 
We suggest messaging shouldn’t focus on the technology and details of the science or the clinical 
and research divide, because these things are too complicated to take on board through direct 
messaging, and in any case these technical details were not required by the dialogue participant to 
understand the broader issues such as the uncertainty of diagnosis / treatment, the probabilistic 
nature of a genetic test result, and the fact it has familial implications 
Instead, we recommend that the NHS explain the paradox in genomics: that an individual’s data has 
little to add to understanding health whereas data submitted by a crowd of people is much more 
likely to yield insights.  Only by building and analysing a ‘genomics library’ will patients get individual 
benefits.  
This is an important aspect of any communications as it helps people engage with the idea of the 
benefits of altruism and altruistic benefits, and speaks to a common worry that researchers are 
spending their time looking at just one individual’s patient record.  
There was interest in how / whether other countries are looking to mainstream genomics, and the fact 
that the UK is a trailblazer struck a chord with participants. Genomics can be framed as one of the 
UK’s success stories, although this should not be the primary message as healthcare, rather than 
economic growth, appears to resonate more.   
“We seem to be quite far behind.  Are we catching up here?  If America has already introduced 
[genomics] into healthcare, where are we?” Coventry event 2 
Policy makers should tell the public that genomics benefits won’t be realised without a partnership 
between the NHS, research community and commercial companies. This needs to be explicit given 
the knee-jerk reactions to private sector involvement in healthcare. There is therefore a need for a 
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description of public and private partnerships in layman’s terms, and a crystal-clear explanation of 
how genomics is funded (who is paying for what?), and whether and how benefits are reinvested.  
6.3 A mission statement for genomics 
In the longer-term, genomics will need a call to action - if the new social contract is going to work the 
public will need to know what genomics is and be motivated to take part, so there is a need for a 
mission statement that conveys the idea that success needs solidarity, altruism and reciprocity. We 
can infer from the participants’ discussions, and expert input, with regard to the social contract in 
genomics that the following statement may work as a call to action, as well as communicate the 
essence of the social contract in an intelligible way.    
“People powered genomics”. 
 
As genomics evolves, further public and stakeholder engagement may be needed to ensure the social 
contract remains relevant and instructive.  
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7.1 Next steps from this dialogue 
This project has built on all the work done already which has covered a range of topics related to 
genomics including ethics, law, social contract, consent, NHS capability, and funding; it has looked at 
attitudes to health data and data sharing among the public, and population sub groups e.g. BME, and 
stakeholders. This insight, plus the input from experts from a range of private, public and charity 
organisations, as well as contributions from the public and patients have enabled us to offer 
conclusions and advice for what to do next in the NHS Genomic Medicine Service.  
However, there are areas where we would recommend further investigation, in particular around the 
intersection of genomic medicine and research, and the sharing of health data with commercial 
companies. 
The Wellcome commercial access to health data project, mentioned throughout this report, identified 
that attitudes to data sharing are influenced by the context in which it is used. Overall, we found that 
people are relaxed about sharing their data with the NHS because they have an expectation that their 
data is being used on their behalf.   When sharing data consciously in a commercial context, 
customers give their non-health related data, because they get a service they value in return. When it 
comes to sharing health data with commercial companies however, these contexts collapse, and 




In that study we did not specifically explore genomics – but some commercial genomic services 
currently blur the boundaries between ‘commercial’ data sharing, where there is a more wary 
customer relationship, and ‘public sector’ data sharing, where there is an assumption that the 
                                                     
51 https://wellcome.ac.uk/sites/default/files/public-attitudes-to-commercial-access-to-health-data-wellcome-mar16.pdf 
5
     




   
7 Conclusions   
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patient’s best interests are considered.  Some participants in this study bought a genetic testing kit 
from 23andMe and Ancestry.Com, but didn’t consider how their genetic data would be used or the 
possible repercussions of knowing their test result. 
 
We noted that the approach they used to finding out about their genome could be described as a 
‘gamified consumer relationship’. In these relationships, people appear less concerned about giving 
information about themselves when it is seen as “quirky”, a “curiosity” or a “bit of fun”. We would 
recommend researching this context further, to see how far people understand the risks and benefits 
to themselves. If people give their data to a consumer testing company and something happens that 
fractures trust in genetic testing, this could have implications for trust in genomic medicine. 
7.2 Governance framework 
This dialogue also gives us learning on public views of a governance system for genomic data in 
future.  
There was healthy scepticism about how well any data sharing system can ever work in the NHS given 
that it is not known for high tech data management. As one participant said:  
“It’s like a dinosaur, it’s not ready to handle the technology”. London event 2  
Therefore, policy makers and the UK government will need to provide reassurance on the use of 
patients’ data. Specifically, they will need to inform the public that they will remain responsible for 
patient data and ensure the system conforms to the highest standards of data security and 
governance across sectors and national jurisdictions, and be accountable (individually and 
organisationally) if things go wrong.  
 
Researchers only being allowed to access de-identified data if it remains on NHS servers was a key 
reassurance, however there is the possibility that rules around data sharing may evolve in the future. 
Therefore, it will be prudent for those managing and delivering the genomics system to make the 
case for data sharing in genomics and health research more generally: that a global effort by a 
community of experts will help translate researching findings to in clinical care more quickly.  
 
In the longer-term, there may be need for a wider narrative about the changing nature of data usage 
by the NHS and its partners, specifically what the NHS and researchers are doing with donated data, 
which will need to take place on a national level.   
The public understood that a genomic database cannot be 100% secure, and that any database can 
be hacked; while this dialogue didn’t explore attitudes to standards and safeguards (e.g. national 
security standards of data protection), it was felt they need to be of the highest standard.  
Finally, access to data by insurance companies, or other private sector organisations, needs to be 
carefully reviewed, as the new ABI code approach was seen as too ‘voluntary’, leaving too much to 
the discretion of private companies. 
7.3 New definition for equity of outcomes and equitable redistribution  
The literature review and this dialogue clearly show that the public, patients, and experts are all 
concerned about the current and future capabilities of the NHS, and it is clear that the extent to which 
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the public will give their support for genomics will be based on whether it is seen to be delivering 
better clinical outcomes.   
In the short-term, the dialogue participants recognised that genomics is in its early stages and could 
accept that the benefits of genomics won’t be equally distributed across the UK population. They 
appreciated that creating more effective treatments for cancers and rare diseases are very difficult 
problems, and appreciated that the GMS is seeking to build on the lessons learned and insight from 
the 100,000 Genomes Project.   
 
But, in the longer-term, the public want to be reassured that their altruistic act will not be wasted, and 
that the budget for genomic medicine allows all sections of society to benefit fairly. Therefore, policy 
makers will need to build trust by ensuring that any GMS is properly funded, which means that the 
NHS (whether in England, Scotland, Wales or Northern Ireland) has the resource it needs to deliver 
excellence throughout the “genomics pathway”: genomics counsellor, clinician, researcher. The long-
term roll-out should be nationally balanced both in terms of equity of access and outcomes. 
 
The NHS will need to inform the public how much genomics costs in the context of the overall 
healthcare budget; and give a realistic assessment of cost savings over time.  Policy makers and the 
NHS will need to tell the wider public what are the expected timescales for adding other conditions 
and diseases to the genomic test directory52, so as to manage expectations, while maintaining 
support for investing in genomics.  
If the UK public are donating data, this brings in attitudes to the private sector and as such 
participants thought that the public has a right to expect that some of the financial rewards of new 
medical developments will return to ‘UK plc’. And therefore, participants thought that policy makers 
should implement a mechanism which delivers treatments for rare/ultra-diseases, a fair price for new 
treatments, and re-investment in clinical care and research, in recognition of the fact that genomics 
creates new financial opportunities for pharmaceutical companies.  
7.4 Inscribing the genomics social contract in the NHS constitution  
Actors in the genomics system should not use the term social contract; it is not widely understood and 
is not likely to resonate with the public. However, participants in this dialogue concluded that the 
elements of the social contract do need to be written down, and then communicated to everyone who 
has a role to play in genomics.  
The key elements which need to be communicated are the new expectations of behaviours of all actors 
in the system, which we have noted elsewhere in this report. 
“There have to be guidelines in the world of genomics. Everyone has to understand where the 
responsibilities fall.” Leeds event 2  
• Reciprocity   Altruism: Genomics requires donation of data from individuals. This blurs the 
line between reciprocity and altruism. The public in the dialogue saw giving their data as an 
altruistic act -  but also expected benefits would probably accrue to their families and 
descendants.    
                                                     
52 https://www.england.nhs.uk/publication/national-genomic-test-directories/  
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o There would, therefore, be an increased expectation that the public would donate 
data, but participants felt that data donation should not be mandatory. 
o Participants thought that government and healthcare policy makers would need to 
create a roadmap for genomics where the status of data donors is made clear, and 
any rewards for them carefully worked out. 
• Reciprocity   Solidarity: Genomics can use patient data in research and clinical care at the 
same time, creating a feedback loop between both to increase possible learning.  Participants 
felt that this research/clinical blurring brought the ideas of reciprocity and solidarity closer 
together. 
o Both clinicians and researchers in a genomics future would be responsible for ensuring 
that patients and families are informed about the progress of research. 
o They should also focus on ensuring the translational benefits of research to care, to 
benefit all of society, as quickly as possible.  
o Both researchers and clinicians should communicate the progress they are making 
towards discoveries with real clinical impact; so the public can know their collective 
action is worthwhile and having impact.  
• Solidarity   Altruism: In the future, if a large genomic dataset exists, and can potentially be 
accessed by new actors, (such as commercial companies) social solidarity will be affected by 
the altruistic acts of individual donors.  Dialogue participants felt that: 
o Policy makers should take a long-term view – design a future which prevents 
dystopian social outcomes. Participants emphatically did not want their donation of 
genomic data used to create a stratified society which disenfranchises vulnerable 
members.  (e.g. genomic datasets being heavily used in insurance, marketing, etc) 
o There should be a new role for industry in bringing the benefits of genomics to 
society; but either voluntary or external regulation will be needed. Again, participants 
did not want to see the altruistic data donations of individuals used to enable private 
sector profiteering. 
 
Given the profound effect that genomics is likely to have on healthcare in the UK, we recommend 
inscribing in the NHS constitution these elements above; the ways in which genomics adds to, and 
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This annex contains the following documents:  
• Annex A: Event 1: discussion guide, plenary presentation, and stimulus materials 
• Annex B: Event 2: discussion guide, and stimulus materials 
• Annex C: The genomics summit: discussion guide 
  
8 Annexes 
Ipsos MORI | A public dialogue on genomic medicine – FINAL – Public 59 
 
18-045132-01 | FINAL | Public | This work will be carried out in accordance with the requirements of the international quality standard for Market Research,  
ISO 20252, and with the Ipsos MORI Terms and Conditions which can be found at http://www.ipsos-mori.com/terms. © Ipsos MORI 2019 
 
 Annex A  
Genomics: time for a new social contract? Public dialogue to uncover views of mainstreaming genomic medicine in UK 
 
Event 1: 3-hour evening session – 6.15pm-9.15pm.   
 




Arrival, registration, refreshments 
 
 
WELCOME AND PLENARY  
Lead facilitator show slides 2-4 
 
Slide 2: Study overview: study sponsors i.e. GE and SW, and overarching aim:  your thoughts, hopes, aspirations, and concerns about different 
ways people’s genomic information can be used in NHS. Introduce dialogue delivery team, clients, experts/ observer and   
 
Slide 3: The main areas to cover – don’t worry you don’t need to have prior knowledge, we will give you all the information you need and 
experts here who can answer your questions Explain workshops taking place in:  
• 4 locations: London, Coventry, Leeds, and Scotland  
Event 1: evening 
Event 2: day-long, Saturday 
• And a final genomic medicine summit Friday 14th Dec.7 people from each location invited back to the summit.  
 
Slide 4: housekeeping, plus breaks, toilets and fire alarm 
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6.30pm-
7.05pm   
Understanding Healthcare and health data  
 
TABLES 6.30-6.40pm  
 
Facilitator introduces themselves, thank you for coming, no right / wrong answers - really interested in what you think.  
 
Before we do introductions, I’d like you to write down what you think of when I say the future of healthcare in the UK. Here are some post-its and 
I want everyone to write down what they think will be “good or better” about healthcare and on another post its what you think will be bad or 
get worse  
 
Okay so now please tell us your name and what you have written down, each ppt shows 2 post-its each. Facilitator cluster post its on Flipchart  
 
• IF TIME ASK: What do you hope healthcare will be able to do in the next ten years? Prompt on - For you, your relatives, 
patients, people with long term of serious conditions, for different groups like children and the elderly…   
 




Split into 2 groups per table i.e. cc. 5 ppts in each group and handout quiz sheet. In your group, discuss then write down what you think is the 
correct answer. 
 
Facilitator to ask teams to shout out answers.  
 
• Q1 correct answer is a, b, c, d, e. then show slide 6.   
• Q2 correct answer is a, b, d, e, f, then show slide 7. Then show slide 8 – healthcare – it’s not just one thing. 
o If needed, say, in your own words, the following extract from Understanding Patient Data: Companies are involved in many ways 
in the delivery of care and research across the NHS, but there are strict controls on how companies can use patient data, to 
protect your privacy. The NHS can’t do all the data analysis on its own. It has to work in partnerships, with academic researchers, 
charities, regulators - and commercial companies.   
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• Q3 correct answer is a, b, c, e then show slide 9. Then say: information from patient records can be used to help understand more about 
disease, to develop new treatments, to monitor safety, to plan services and to evaluate NHS policy.  
o If needed, say, in your own words, the following extract from Understanding Patient Data then say, in your own words, the 
following extract rom Understanding Patient Data -  The NHS will never share your name or contact details with companies to 
use for marketing purposes, unless you give consent. Pharmaceutical companies have to follow strict rules about marketing, and 
they are not allowed to advertise prescription medicines to patients in the UK. If you are applying for life insurance cover, an 
insurance company will want to know information about your medical history. The insurer will usually ask you questions about 
your lifestyle and relevant family history but may also want to see your medical records. This is only possible with your 
permission. Only if you agree, your GP will then provide the relevant information to the insurer. There is currently a ban on 
insurers using genetic information 
 
Lead facilitator show video: Understanding Patient Data - Patient data saves lives: the bigger picture   
https://www.youtube.com/watch?v=fJ2hyXCOOyQ  
 
TABLES 6.55-7.05pm  
 
• Any surprises in what you’ve just heard? Any questions? 
• Response to info on organisations involved in healthcare. 
• Do you ever think about your health data, or any data about you collected? Did you know about these various kinds of ways 
data is collected?  





Introducing genome sequencing and 100,000 Genomes Project  
 
PLENARY 7.05-7.15pm  
 
Lead facilitator shows video: Introducing genomic medicine, stop video at 4min30 seconds  
 
https://www.genomicsengland.co.uk/the-100000-genomes-project/understanding-genomics/ 
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Facilitator explain that ‘genetics’ is often used as a catchall word when searching for faults in one gene and ‘genomics’ is used to explore 
many genes to find the fault in one gene. They both test the same thing but the genomic test gives you the chance to explore many genes at 
once, in your search for the single relevant one. The key relevance of ‘genomics’ being important is that it offers a rich set of data that can be 
used in all sorts of research.  
 
Lead facilitator show slide 11, introducing the idea that genome sequencing has become a lot cheaper and results are known a lot quicker due 
to advances in “reading” DNA and computational (computer) capabilities, so it’s more accessible to people.  
 
TABLES 7.15-7.25pm  
 
• How does that sound? Do you like the idea of genomic sequencing being made available to more people? Are there any pros and 
cons?  
 
• Have you heard of any organisations collecting genetic / genomic data? E.g. 23andMe, AncestryDNA, Genomics England, Illumina etc.  
 
• Can you think what these organisations are collecting genetic / genomic information for? E.g. People’s curiosity in their ancestry, 
curious about their chances of developing a genetic condition, have an undiagnosed health problem 
 
• How do you think genomic data compares to the types of patient data health we discussed at the start? It is more / less 
sensitive / useful than the kind of health information in your medical record?  
Table facilitator show slide 12, introducing the idea why genetic information can be useful 
 
• What impact do you think collecting more genetic information will have?  
 
o patient / person / family: give certainty, or prolong uncertainty, influence decisions affecting lifestyle, life planning,  
o increased demand on primary care such as GP / support  
o UK more attractive place to do health research / biomedical science.  
 
PLENARY 7.25-7.35pm 
Representative from GE show slide 13 introducing the 100K Genome Project and then 14, introducing the idea why genetic information, and 
linking it with other health data and lifestyle data can have clinical and research benefits.   
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• Any surprises in what you’ve just heard? Any questions?   








Experts with different points of views discuss their hopes for, and concerns about, making genomics / genomic medicine part of routine NHS 
care   
PLENARY  
 
Depending on numbers at each event, 2 or 3 experts spend a few minutes introducing their area of work / professional background in plain 
English / layman terms, then explain what they see as benefits and risks What are their hopes for rollout?  What they think the key issues are? 
 
Table facilitators invite experts to talk to ppts / answer their questions.  
8.15pm-
8.50pm   
Making genomic medicine part of routine NHS care 
 
TABLE DISCUSSION 8.15-8.50pm  
 
Okay, we’ve heard from people who are involved in the 100,000-genome project and genetics services. Now we’re going to hear about how 
the genomics medicine service will be phased into the NHS and I will ask for your thoughts. Again, experts are on hand to answer your 
questions. So, if everyone looks at:  
 
Who will genomic medicine be made available to first? 
slide 16 Facilitator note: key take-aways are: who WGS will be made available to and on what basis and setting the target for how many 
genomes will be sequenced in the next five years in the context of how many sequenced in the 100k GP.  
 
Was there anything you didn’t understand / expect to hear? Invite questions from ppts and flipchart as will feedback in plenary. Ask why it’s 
important to know and invite experts in to answer questions 
 
What do you think of what it says? Probe: good, optimistic, bad, worried?  
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Now let’s all look at:  
 
Making genomic medicine a part of NHS care -  data about your genome  
 
slide 17 Facilitator note: arrangements for data storage security, organisations which will have access to genetic data and for what purposes, 
process for obtaining access.    
 
Was there anything you didn’t understand / expect to hear? Invite questions from ppts and flipchart as will feedback in plenary. Ask why it’s 
important to know and invite experts in to answer questions 
 
What do you think of what it says? Probe: good, optimistic, bad, worried?  
 
Is it fair to opt of out of research and planning? What if scientists find out something that could be useful in clinical care?  
Any surprises in terms of what organisations can access genetic information? How do you feel about that? Can you think why data might be 
analysed and interpreted by researchers working in commercial companies and / or around the world? What do you think about the 
arrangements for data storage and access? Do you need to know they exist or how they work? Why?  
 
Now let’s look at:  
making genomic medicine a part of NHS care (3) – your result and your primary care   
 
slide 18 Facilitator note: anticipated impact of genomic medicine on patient engagement with primary care services, the HCP-patient 
relationships.  
 
Was there anything you didn’t understand / expect to hear? Invite questions from ppts and flipchart as will feedback in plenary. Ask why it’s 
important to know and invite experts in to answer questions 
 
What do you think of what it says? Probe: good, optimistic, bad, worried?  
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What do you think of the way the genomic test result will be fedback to the patient? What role should other family members have, given the 
results says something about them too? What impact do you think genomic medicine will have on health care services? How might it affect 




Hope and concerns for genomic medicine in the NHS.  
 
Okay, so we want you to think about what the experts have told us as well as everything you’ve heard tonight. Now, we want you to work in 
groups of 3 and write down on post-it notes your hopes and concerns for genomic medicine in the NHS.  
 
No limit on the number of hopes and concerns but do rank your top 3 in each.  
 
Facilitator invite 2 or 3 groups to present top 3 and invite others to compare. Then ask all: on balance, are you optimistic or concerned about 





Thanks and close 
 
• Homework task: genomics conversation and online search, if do complete and bring back we will give you an extra £5.  
• Questionnaire knowledge of and attitudes to genomic medicine in the NHS, used for segmenting groups at next stage 
• Evaluation questionnaire 
• Hand out incentive 
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 Annex B  
Genomics: time for a new social contract? Public dialogue to uncover views of mainstreaming genomic medicine in UK 
 














Arrival and registration, H&S briefing 
10 -10.15 Revisit introductory slides plus add slide on key aim for the session. 
We have 3 aims today 
Focus on a wider use of genomic medicine, in the NHS and beyond: your views of its benefits, any concerns you have, and 
any safeguards you’d expect 
o Discuss what might happen in practice and what you think is acceptable and not acceptable in different situations 
o Finally, decide on what patients and the public would ideally contribute; and what they should expect back from, a 











Introductions on tables On tables divided by age  
Review of post-task at tables 
 
Experts brief introduction (10 min)  
3 mins each on their table.  
Participants question experts, assisted by facilitator. to be confirmed when we know who is coming: will share questions in advance 
• Experts explain their experience of / role in genomics / area of academic, clinical or business interest 
• What benefits do they see from a wider use of genomics in the NHS?  What challenges will there be? 
• What might change about our expectations of or experience of medicine? [issues relating to social contract] 
• What specific ethical issues do they see that they would like the public to talk about today? 
• For the public: what further questions would they like today to answer? 
• After last expert, each table feeds back to facilitator: 
o Learned anything new/surprising? 
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Have your opinions on anything changed, or are you now thinking about any new questions? 
 
Spontaneous views on expectations, benefits and risk of genomics (30 min) 
• Spontaneously, what do you think will be the top 3 benefits of this new medicine? To you, your family and children, and then to 
society as a whole? Why?  Facilitator to capture on cards –one for each benefit 
• What are your expectations or assumptions as to what could be done with your whole genome sequence? What kinds of things 
do you think could be found out?  
 
Initial probe on issues around social contract Capture on flip chart 
• To have these benefits – very briefly, what would you expect the public will need to do, or agree to?  How acceptable would you 
find it to give your genetic data as part of your care?  
• How about giving your genetic data as part of the overall research process? Does your opinion depend on whether you would 
receive care, or not? 
• Some scientists feel - As a society we are at a tipping point - data must be donated and shared and we all need to be in this 
together to improve human health. A partnership is needed.  – what are your views? 
• What proportion of the population do you think would need to share their genomic data to provide a really good service? 
• Is this partnership different from the way healthcare has been delivered up to now? Will anything be different? i.e. how the NHS 
might behave, what you might need to do, what researchers or private companies involved in the system might need to do? 
• What concerns do you have, at this stage? Are there any unintended bad consequences that might come from bringing a 
genomic medicine service into wider medical practice?  
 












11am – 12pm Exploring the trees 
 
To tell the story of how some people might engage with genomic medicine, we have built three family trees.  Each table will look at one 
of these. The first questions relate to things which might happen as genomic medicine is used. This helps us to talk about some of the 
practical and ethical issues – we’ve been given the ideas for this part by the experts we have spoken with.  
 
The second questions are ideas we’ve come up with ourselves, to push the boundaries a bit. 
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expectations 
around it.  
Stimulus material: facilitator will have a blank flip chart page to start with and they will add stick-on pictures of the family members and 
summaries of key issues. 
 
For each tree: 
At each point participants are asked to reflect on what is happening to the character. Facilitator will follow the prompts below but will 
need to cover the following issues: NB – these are all questions which relate to participant expectations of the social contract 
 
• What should the NHS help these people with?  
• What advice and guidance should they be given, and by who? 
• How should people hear about genetic results (letter, meeting, etc) 
• At what point should these people be given choices about their care and about the use of genomics in the process? 
• What is acceptable or unacceptable about this situation? 
• Do you see any tensions here between different ethical concerns? 
• If different members of the group disagree – if this happened in real life, how should disagreements be resolved? 
 
First tree: The Miller Family 
 
1) Tom and Lauren have a baby with learning disabilities. The baby, Evie, has a whole genome sequence. The data is kept on at least 
two databases, the NHS Genomic Medicine Service database and the research database Decipher, used by the NHS. 
 
What safeguards should the parents and baby expect to apply to that data?  Tom and Lauren could refuse their baby’s data being 
added to the research database.  How do you feel about this?  
 
Note: Tom and Lauren will be able to opt out of their data being in Decipher (and according to Mark B, they will be able to opt out of 
their data being in the research arm of the GMS database, from what I understand). However, they won’t be able to opt out of their 
data being in the clinical arm of the GMC database - this is going to be the way that they actually get a diagnosis, although in reality 
at the moment, the best way to get a diagnosis is to be in the Decipher database as this focusses on developmental disorders and 
learning disabilities. But basically the message of what you are wanting to get across is there are two types of database - clinical and 
research. Clinical is mandatory, research is optional, but to get the best individual outcome it is best to be part of both, but what 
comes with this are different levels of governance.  Particularly for rare disease this is VERY relevant. If a kid is the only one in the UK 
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with a rare developmental disorder you want to be able to compare their genomic variant with data from Iceland, Australia etc and 
that’s not going to happen from the NHS database. Other databases will have to be used in the NHS 
 
 
2)  Lauren discovers that she has a BRCAI gene alteration predisposing her to breast cancer. This was an ‘additional looked for finding’ (as 
it’s on the list of tests that can be given) in the sequencing of the genome of the three of them. She would be told the information if she 
wanted to know. Should she be allowed not to know?  She is not certain whether she will get breast cancer. She has a history of anxiety 
and worries a lot now about breast cancer.   She could have genetic counselling to identify whether she could just wait until Evie was 
older and test for her own sake. 
 
3) Lauren has two sisters, Gemma and Briony. Gemma is Lauren’s twin. They have a 50% chance of having the same gene alteration. 
Lauren tells them of her diagnosis. Gemma knows she has the same mutation.  Briony refuses to test. Later in life Briony gets breast 
cancer which is treated at a high cost by the NHS. Overall, her care has cost much more than if she knew about the issue earlier (even if 
she’d had a mastectomy).   
 
4) Or – Briony does have it done, she has a preventative mastectomy which causes her much distress. But she never knows if she would 
have got breast cancer at all.  Genetic information in this case is about a propensity to have something, could there be a harm to Briony 
knowing about her diagnosis rather than taking her chances? 
 
5) Lauren has another sister Hannah but they’ve not spoken for years. Lauren does not want to tell her anything about it.  Does Hannah 
have a right to know she might have this?  Does Lauren have a right to privacy? Does it make any difference if she also has a daughter? 
 
6) Lauren’s parents Des and Elaine tell Lauren’s aunt and the aunt, Diana, asks for whole genome sequencing for her daughter, Emma – 
she is very worried that her daughter might get breast cancer.  NB she won’t get this, as it’s not recommended - should she be allowed 
to ask for this, if it is not something she is offered? 
 
7) Evie’s data is de-personalised and shared with a number of researchers and included in large, international linked databases. Would 
you have any concerns around this?   Commercial companies e.g. pharma developing treatments for some of her conditions have access 
to her data, including companies based in the US and China.  
 
And more boundary-pushing examples….  
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8) Evie’s data is kept forever. Does this matter? She hasn’t consented. How about if in the future, genome sequencing can be done on 
people not just with learning disabilities etc but less visible conditions (diabetes, asthma).  It would likely still be illegal for employers to 
ask for genetic test results.  It was pretty firm under the old Data Protection Act, and likely even harder to justify under the new DP Act 
2018 / GDPR.  Is this enough for us – would we trust that these protections will protect employees? If data is leaked, even if illegal, would 
you think employers would look at it?  Is it worth the risk for you, given the other considerable benefits of genomics?  
 
9) Evie dies quite young. Lauren and Tom want her data removed from the research database. They can’t have this; it has been de-
personalised and it cannot be removed from all the projects in which it’s been used, though can be removed from future studies. Should 
they have been told about this upfront, more clearly?  Will people ever take it in?  NB facilitator to make it clear that removing data from 
published studies is not feasible – studies might have been shared and used, can’t keep changing one percentage point etc.  
 
10) Diana doesn’t get the sequencing for her daughter, but she does end up in a research project which sequences her genome. She also 
goes to a private company and uses a DNA test to identify her ancestors.  She posts the answers on social media.  Research has shown 
that it’s easy to identify people if they do this – if you’re a European-descent individual you get a third cousin or closer match, which 
makes the group of people small enough to permit re-identification.  A PPI company (not based in the UK but which has access to her 
social media data) links her by name to the genomic information.  Diana suspects (doesn’t know, but suspects) that this company now 
has her personal phone and social media data, the health record about her, and her genomic data. She is very worried about this. Like 
everyone, she gets cold calls about PPI but wonders if it’s because her data has been leaked. The company says that all records are kept 
separate.  Should Diana have had help to weigh up the risks of putting her genomic information in the public domain? What kind of help 
is feasible?  
 
11) In future, Briony and Gemma are asked to disclose whether they have had genetic testing for insurance – Briony has a higher premium 
as she has had breast cancer. Gemma has a higher premium because of the family history.  The insurer takes into account Briony’s risk 
reducing surgery. But is it fair that they have the higher premium? 
 
Second Tree: The Cooper Family 
Paulette and Hubert have two sons, Benjamin and Frank.  
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1) Benjamin has a rare condition and is offered WGS in the new rollout of genomics.  Paulette and Hubert are worried by this - 
they’ve been scared by the Windrush scandal, which has affected some of their friends. They are concerned about anyone taking 
their data and “putting it in a database”. Should they have the right to refuse the genomic testing? How can they be reassured? 
 
2) Frank’s son Chris also has a suspected rare condition.  He is offered WGS. The results take a long time to come back – just over 3 
months. Frank is very concerned through this time.  What support should Frank and Chris get?  
 
3) Chris and Frank are both diagnosed with a rare condition that has no cure.   
Chris is in good health through his teens and his symptoms are not too bad but as he gets older he gets more depressed about 
his future.  He engages in risky behaviours which make him more ill, seems angry and upset. Should he have been told about his 
prognosis?   
 
4) Paulette’s sister, Caroline, has a son called Jacob. He is fit and healthy, a keen sportsman, and works in the police force. Jacob is 
offered WGS due to his cousins’ health.  But he doesn’t want his genome screened.  He is worried about future uses of genomic 
data. “I trust my colleagues but you always hear about the odd bad apple in the police.  How about if I’m at a crime scene, and I 
work for a bad boss who wants to fit me up for a crime? With my genetic data out there, I might be at risk”.  There are no plans 
for the police to access health data. (And in fact Jacob could be ‘fitted up’ with a hair or cigarette butt at the scene) How 
reasonable is Jacob’s concern? What sort of protections would reassure you if you were in Jacob’s shoes? How should we balance 
concerns like these, relating to the future, with the benefits of genomics- for Jacob and for all of us?  
 
5) Suddenly, one day while playing football in his work team, Jacob falls down with a sudden cardiac arrest. It turns out that sadly, 
he is a victim of sudden cardiac death.  He has not had genomic tests but after death a genomic test reveals a genetic alteration. 
Could he have been saved with a screening? At what cost to the NHS of screening everyone? Alternatively, Caroline decides she 
doesn’t want his genome examined. Does she have the right to do this, because if the death was to do with the genetic 
component, it might have a bearing on other members of the family?  Assuming the rest of the family hadn’t been screened, a 
different situation - should the NHS tell the family? And screen them?  
 
More extreme examples: these are very future focused. 
 
6) Some years after Hubert’s screening, he finds out he has a “Polygenic risk score” which is a mixture of risks for how likely he is to 
get cancer.  He has a ‘lucky’ combination of lots of gene variants that individually have no effect.  The results are usually given 
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along the lines that someone is 2 or 3x more likely (or less likely) to have cardiovascular disease.  So he takes these results quite 
literally and thinks he won’t get cancer.   He’s been trying to give up smoking but joyfully now he starts up again.  Within a year, 
he gets lung cancer & dies. Would he have been better off not knowing this? How should we inform and protect people about 
the way that this information can give people a likelihood of something?  A further point – at the moment, scores are more 
accurate for people of Caucasian / European descent and not other ethnicities… does this mean we should inform people 
differently about this? 
 
Third Tree: Ahmed family 
Nazir and Atef Ahmed have one son, Sadiq.  He was married to Azra Ahmed and they have one child, Basma.   He divorces Azra and gets 
married to someone else, Stephanie Ahmed {nee Smith}.   
 
1) Sadiq and Steph want to have a baby. But it’s not happening, so they go for fertility treatment.  At the fertility treatment they are 
offered genomic testing.  Sadiq has mild cystic fibrosis.  The genomic sequencing confirms this has affected his fertility and he 
can’t father a child.  In the counselling session, Sadiq realises that Basma can’t have been his child. What should happen from 
hereon? Who should approach Azra, if anyone? Has Azra’s right to privacy been infringed?  What help should they all get? 
 
2) Atef was offered whole genome screening when Sadiq was under 16, to be part of a research study tracking children from birth.  
(e.g. risk factors for children from BAME backgrounds in socially deprived areas). She decided not to tell Sadiq and he was not 
screened. Is that fair?  
 
3) Nazir goes to 23andme and finds out that he has a genetic predisposition to Alzheimer’s.  He is angry and upset and goes into 
his GP, demanding some kind of treatment right away. The GP says there is nothing that can be done, and maybe he can just try 
and keep as healthy as possible.  If Nazir doesn’t heed this advice, does he bear any responsibility for his health in later years? 
How about if Nazir decides to live life to the full, takes up some new hobbies, travels to Pakistan to see family, a trip he’s been 
putting off for years?  He has a better quality of life, living in the knowledge of the diagnosis.  Is it acceptable for companies (or 
the NHS) to deliver results from genomic tests where there is no clinical treatment available? 
 
More extreme examples 
 
4) Steph and Sadiq do eventually have a child (through donor sperm), called Jadon. He is born deaf.  As he gets older he becomes 
part of an activist group championing the ‘right to exist’ of deaf people. His group claims that genomic screening of embryos is 
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leading to more mothers deciding to abort embryos which show genetic issues such as genes associated with autism, deafness, 
learning disabilities and dwarfism.  He wants this sort of screening to be made illegal. Does he have a point?  
 
5) Steph, later in her life, develops bowel cancer. Her cancer genome is screened. Fortunately, there are a range of drugs available to 
treat this particular kind of cancer. Steph is offered a particular drug by her local Trust.   She goes online and finds that there are 
other drugs which are thought to treat the cancer better. Her care team explain that genetically, she’s best suited to the drug she 
is on. She does not believe them and thinks she’s just on a cheaper drug. She travels to the USA to try and get a different drug.   
Is it reasonable of her to try and alter her care plan like this?  How about if it is actually a cheaper drug, but which treats the 
cancer well but maybe not quite as well as the specific drug for her genome, which American doctors recommend, but which is 
not recommended by NICE due to cost-benefit analysis? Should the NHS be offering cancer genome screening if it cannot offer 
an entirely personalised treatment regime? 
 
Final example -should always be done last after all 3 families completed – by each facilitator? 
 
Steph has another baby. At this point, the neonatal heel prick test has been replaced with automatic whole genome screening of the 
baby. All the babies are now part of a lifetime of potential uses of their genomic data (revisit talking head from data privacy). Is this a 
world which is acceptable, scary? Are there safeguards you can think of that you would put in place?  Is it inevitable that such a world will 
come to pass, if we roll out genomic medicine? 
 
At the end of the session facilitator to prep the team to respond to plenary feedback 
 
12-12.20pm  
Feedback from each table 
• Most important issues you discussed 
• Three principles for how genomic medicine should be used in wider society, based on your conversations 
• IF TIME: what was different about genomics medicine in these scenarios compared to the dilemmas in conventional medicine 
 
12.20- 1.00 LUNCH: after lunch, lead facilitator to do a washing line:  One end of the room is “genomics in 10 years time is wildly successful” – the other end 
“genomics has led to undesirable social consequences” – please position yourself on this line 
Facilitator divides afternoon groups based on this.  
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Drawing up the 
social contract 
(NB this will 
also be 
considered in 
detail at the 
Summit) 
(15 mins) Plenary discussion of social contract 
• Have you heard of the term ‘social contract’?  What does it mean to you? What does it mean in medicine and healthcare, 
particularly? 
• We could describe it as “The shared, reasonable assumptions and expectations that everyone in the system has, which guide how 
the system works” 
• Why is this important (if you think it is important)? 
• Who decides on how the ‘social contract’ works? 
• Who has a role to play in making sure it is held to – government, citizens, patients, researchers, companies, charities… who else? 
 
(35 mins) In tables, each facilitator has a flip chart.  This is a large template that the table will fill out together 
Lead facilitator to explain the template in plenary. 
 
Over the next 3-5 years we are thinking about people’s expectations of genomics and medicine. What does everyone in the system have 
to do, to make genomic medicine a success?  What would be additional ‘nice to have’ things that different players can do – and what are 
your red lines – what can never be done?  In this section we want you to think about the reasonable expectations you have about 
genomics – what would create good practice.  
 
Each table will have 3 audiences to work with, out of the 6 we have here, then we’ll feed back. 
 
• Group 1 look at NHS, patients, researchers  
• Group 2 look at NHS, patients, insurers  
• Group 3 look at NHS, wider public, UK government  
 
 Who? Have to do Can do – nice to have No way! Must not do. 
1 The NHS and 
clinicians 
Example: give everyone access 
to genomic testing if their 
symptoms suggest they need it 
 
Example: offer genetic 
counselling 
Example: operate a 
postcode lottery 
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2 Patients in 
the genomic 
service 
   
3 The wider 
public 
   
4 Insurance 
companies 
   
5 Researchers 
– in industry 
or academia 
(facilitators 
to tease our 
differences) 
   
6 UK 
government  
   
 
Facilitators to prompt, making sure to pull out the following issues: 
• Is it acceptable that people can refuse to contribute their data to health research whilst benefitting (i.e. in clinical care) from the 
use of other people’s data? How should people who refuse to share their genomic data be treated by the NHS? 
• If genomics only works if there’s a large number of people contributing, how do we make sure this happens? How about if the 
number required is a smaller proportion? 
• Do you see giving data as a ‘payment’ for the genomic service? 
• Do you see genomics as a mainly research process or a mainly clinical process (sort of – for society, or for you? A common or 
private good?) 
• How should the public be involved in decisions on this going forward? 
• How should the benefits of genomics be distributed – how do we make it fair? 
• What are the expectations of researchers – how quickly do they need to benefit patients, or do they at all? Does it make a 
difference if they are funded through charity, industry, or the state? NB increasingly health research needs to be undertaken by 
multi-disciplinary teams – because, broadly speaking, we’ve discovered the easy stuff) so it’s common for academic researchers to 
work with scientists and researchers in the commercial sector.  
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• Economically – how should we make money from this, if at all? If university research comes up with intellectual property – how 
should they decide to use it? How should they balance commercial value with patient benefit? NB according to Professor Tim 
Hubbard, academic researchers get data for free while commercial researchers already pay for this.   
• How should insurance companies balance commercial interests with a duty to society (if in fact you think they have this duty). 
• What are your expectations of UK Government in all of this? How should the UK government fund genomic medicine, given 
current pressure on the NHS e.g. ageing population? How should the government be involved in decisions on this going forward 
e.g. safeguards, code of conduct for insurers, giving organisations outside healthcare permission to access the genomics 
database?  
 
(20 min) Plenary feedback.  Each table feeds back their chart 
• We have established something of a ‘social contract’.  Do we need to write this down – or can we trust the NHS to run according 
to these principles anyway?  
• What might help/prevent the NHS adhering to what we want? 
• Who has the authority in the social contract as you see it? If the NHS has the ultimate authority to make decisions on healthcare, 
what does it need from the public to enable it to do this? And from other actors.  
• Preventative future vs treating you when you’re ill - How far should the state secure our health, treat us, or help prevent us 
getting ill? Is it the job of the healthcare system to help us all to flourish – or to fix problems? Or something in between? 
• Is a preventative NHS based on a different ‘social contract’ than the one we’ve had before? 




Insurance Insurance  
New Code of Practice for insurers has just been issued – this is not a binding law but a code to which the industry signs up – it is 
nevertheless taken very seriously by the companies involved – the members of the Association of British Insurers which have signed up to 
the Code. NB if needed make it clear this is not about private medical insurance.  
Facilitator to hand out summary points on a handout 
 
• An insurer will not require or pressure an applicant to undertake a predictive or diagnostic genetic test in order to obtain insurance.  
• The results of a predictive genetic test may be considered in an application for insurance only when both of the following conditions 
are met: 
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1. This Code states that the specific predictive genetic test may be considered and; 
2. The sum assured exceeds the financial limits set out in this Code. 
 
Going through the detail 
• Before we all go through the detail, can anyone tell me what a predictive test is? How about a diagnostic test? Facilitator asks 
expert to explain terms before moving on.   
• Is it right that you should not have to undertake these tests to get insurance? Pros and cons? If tests are there, shouldn’t we use 
them to get the cheapest premiums for everyone in society? How about if you want to have your test considered? Should you be 
allowed to? What might be the wider consequences? 
• NB – you can voluntarily disclose your test result if it’s in your favour, for instance ruling out that you have a risk that’s present in 
your family history. 
• Is it important that predictive tests are considered differently from diagnostic tests? Why? 
 

















Type of insurance Financial limits above which 
predictive genetic tests may 
become relevant 
Medical conditions for which insurers may 
ask for and take account of predictive test 
results, for policies above the financial 
limits 
Life Insurance £500,000 (per person) Huntington’s disease  
Critical Illness Insurance £300,000 (per person) None 
Income Protection Insurance £30,000 per annum (per 
person) 
None 
All other types of insurance Predictive genetic test results will not be asked for, or taken into account, 
whatever the level of cover. 
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• These are the cases where insurers might ask for predictive tests – what do you think? Financial limits? Types of insurance? Types 
of conditions?  
o Facilitator explain that Huntington’s is unusual that it is a single gene, and there is a very high probability if you carry the 
faulty gene of 1) developing it 2) passing it to your children.  Further information: there are around 4000 inherited disorders 
caused by single gene, or Mendelian, disorders. As noted Huntingdon’s is one, others are cystic fibrosis and sickle cell 
anaemia. 
• Are there any conditions where you think predictive tests should be allowed? Are there any here you’d change? 
• Any final concerns or questions about the use of genomic information by insurance companies? 
• Further info on financial limits, if participants ask - 65% have less than £100K of life cover (probably because they are older term 
policies that decline as a mortgage is paid off). (will also bring along slide)  
 
NOTE FOR FACILITATOR: We have the financial limits because any policies below this will never require disclosure of predictive test 
results.  So we say that at least 95% of applicants can be 100% reassured. 
 
Above the limits an applicant may need to disclose predictive test results if they are in the list of tests in Appendix 1.   
 
Huntington’s Disease for life insurance was the first application made in the old system (2001) and, because of the concerns this raised, 
was the only application under the old Moratorium. 
 
It’s possible that the ABI will make future applications for other predictive tests.  These are likely to be single gene disorders, but may not 
be for life insurance.  For example, critical illness policies pay out on a diagnosis of cancer so some of the familiar cancer risk genes are 
potentially relevant to very large CI policies. 
 
We don’t know when this might happen but the point of the annual report (and 3y review) is to be more transparent about levels of 







data – and 
Use of data about you; risks and privacy 
• Now we’ve thought a bit about how genomic medicine might be used, what are your expectations of the way data about you is 
protected, if you are taking part in genetic medicine? 
• Who would be ultimately responsible for its safety? 
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potential future 
uses of data 
 
Tables 
• How do you feel about international uses? Commercial uses?  
 
We have spoken to some data privacy campaigners and other commentators about the concerns they see; here are two imaginary 
interviews (NB, invented by Ipsos, a mashup of different interviews and perspectives) 
 
View from campaigners about some of the negative aspects of genomics (A) 
Stimulus: Show talking head 
• What surprised you – any food for thought here? 
• Any concerns given this  
• Any questions for experts 
• How important is it that genomics helps us economically? How should the benefits of this be distributed?  NB – new drugs and 
diagnostics are always developed by industry not in the NHS – could there be a proportional profit allocation? How should this 
work? 
• What would be the ideal public engagement around genomics – now, and as it develops?  This campaigner thinks that decisions 
about genomics could be a ‘slippery slope’ – that if we agree to one thing, then another, we might end up with something we 
don’t want (e.g. Eugenics).  But shouldn’t we take each decision as it comes, and take into account how technology works and 
what happens, rather than deciding everything on principle? What do you think? 
• If your data can be identified – does that change your views?  Views are divided here – it’s likely to be a small risk and it would be 
illegal to re-identify data – how should the risk be calculated? Should the NHS prioritise keeping data private, or some of the 
other benefits of genomics? How should they decide? 
• If industry is needed to make genomics work – how do you feel? Is it necessarily a good/bad thing?  Facilitator to give example of 
positive work between industry and genomics - Alexion, a company validating a target gene for the development of new drugs for a 
rare childhood kidney disease. Usually people with this disease die before they are 15.   Alexion have identified 10 undiagnosed 
patients in the GE Rare Diseases Cohort who carry the disease.  They have given the information back to the Genomic Medicine 
Centres the children can now be treated with current best practice - hopefully preventing or delaying the onset of kidney failure.  It 
also allows for genetic counselling on any risk to future pregnancies. 
 
View from data privacy campaigns (B) 
Stimulus: Show talking head 
• What surprised you – any food for thought here? 
• Any concerns given this  
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• Any questions for experts 
• If you were part of the research pool what would be your expectations – of knowing about findings, of having treatment if 
necessary? 
• How do you feel about a national DNA database? The point is not that the databased is designed to be used by others outside 
the health sector, but that it might be in future, once constructed. 
• If data is lost or leaked – what might be the harms to people?  
 




Final post it 
exercise / 
green dots 
Looking at all the flip charts we created earlier, expressing our expectations for a social contract; go and take a look and add a green dot 
to anything you think is particularly important.   
 
Also, add a post it note if anything has been missed – in the light of the discussions we just had about privacy, potential future uses of 
data, insurance etc. 
3.40-
4.00  
Wind up / 
housekeeping 
 
• Housekeeping re. final Summit 
• Event questionnaires 
 
Facilitator notes on some benefits / probes 
Individual 
 
o more precise, personalised healthcare [ability to identify what drugs etc work on different people] 
o tailored treatments [ability to identify e.g. how cancers respond] 
o improving life for people with long term conditions [future inclusion of things like asthma in genomic research priorities] 
o cures for diseases we can’t currently treat [e.g. maybe heart disease, asthma, diabetes, irritable bowel, autoimmune disorders?] 
o better diagnoses if we can’t treat something [e.g. the Charlie Gard type cases where there isn’t consent on the diagnoses, that might 
become rarer] 
o getting your medication right [stopping you taking something that you might have taken for ages but never worked as well as it 
could have done] 
o speeding up medical science [saving money and time in the NHS] 
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Wider society 
o Understanding more about the diversity of human behaviours [e.g. genetic causes of mental illnesses – could this help us be more 
tolerant as a society?] 
o Changing understanding of what the genome means, how the body works [could this lead us to live generally healthier and happier 
lives and make better choices for ourselves?] 
o Chance to carry on world-leading centralised medical system to the next stage [UK is in a good position to do this given the way the 
NHS is funded and run? Emphasise the point that industry and NHS can work together successfully] 
o Targeted service planning [knowing more about the population gives us the ability to understand future needs of population?] 
o Understand the link between disease, genes and environment across the world [make sure to say that to do this, we need to access 
VERY large datasets of linked genomic and health data - not just within the NHS, but globally, between countries and across 
geographical boundaries] 
 
• Are there any other benefits you see – maybe other ways a set of data about our genomes could be used?  NB prompt gently on e.g. police 
usage of a database collected for health use, as we do not want to get into dystopian future uses – but do want to capture any sense of 
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 Annex C  
 
Summit structure 
● c.21 public participants, c.21 stakeholder/OG/patient panel voices 
● Refreshments/biscuits etc on arrival 




Then groups split by 
stakeholder type to 
warm up so public 
participants aren’t 
intimidated. Possibly 
4 groups only at this 
stage. 
Presentation: what we’ve learned so far:  few thoughts from all the locations.    Presentation from Viv Parry / Ann 
Dalton reminding us of key themes, why genomics is important/different from other forms of healthcare. Show film.  
Today we are talking about expectations around healthcare in the future of genomic medicine, and the values and 
principles we all want to preserve. Emphasis on collaboration and ensuring that everyone’s voices are heard.  
Exercise:  picture sort [lots of abstract and non-leading images] – picture that makes you think about the values of 
healthcare, or the shared social understanding we have. Picture of hope for future, and concern for future. – probe on 




Tables split into new 
groups - mixture of 
ppts from across 
locations, and 
stakeholders 
Introductions of new tables.  
The values on which a social contract is based and the founding principles of the NHS  
What would you say are the founding principles of the NHS?  What values are important to the NHS and us, as 
citizens?  (facilitator to collect) 
Then we present the founding principles (as in Generation Genome) 
1) availability of healthcare on basis of need and independent of ability to pay 
2) healthcare of a high standard of excellence 
Spontaneous response: What are your thoughts on these principles?  How do these fit with today’s 21st century world 
of healthcare? Is there anything else happening today (outside genomics) which affects these principles? How should 
we protect or amend these principles, to accommodate genomic medicine?  
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How does these principles relate to you in a world of genomics – what are the rights you feel you have, and the 
expectations you feel are placed on you?  
What would you say the rights and expectations and obligations of the public in general are, to make this work today?  
Of the government? Of the NHS itself? 
What principles do we want most to preserve in healthcare of the future/world of genomics? Each group collect 




Lunch break & do vox pops 
1-35. 
1.45pm 
Plenary – lead 
facilitator presents 
next exercise 
Around the room we have 5 stations.  They relate to different areas where genomics could make a difference to our 
healthcare. In each area Ipsos MORI has invented ways to bring to life some of the ideas we discussed at the previous 
stages of this dialogue.   
These are all made up by us – they’re not future policies or plans from Genomics England – just ways to talk about 
positive and negative things that could happen if genomics is used in different ways.   
We’re going to discuss what we think of these ideas and also consider all the players in the system – patients, the 
public, government, researchers, the NHS, clinicians… 
1.45- 
2.40pm 
Each group rotates 
around first 3 
stations 
 
Our 5 facilitators stay by their stations, while each group (made up of public and stakeholder participants) rotates. 
1:  1.45-2.05pm 
2:  2.05 – 2.25pm 
3:   2.25-2.40pm 
2.40 – 
2.50pm 
Short break, get drinks, continue 
2.50-
3.30pm 
Each group rotates 
around the next 2 
stations  
4:   2.50-3.10pm 
5:   3.10- 3.30pm 
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Return to sit down in 
table groups 
Summary of most important principles the group thinks should guide development of genomics in the NHS. Facilitator 
prompts on all areas & particularly focuses in on any issues arising from their own station.  Participants use their own 
booklet to feed back their thoughts.   
3.50- 
4.00pm 
Plenary  Present back – each facilitator/group presents back on their area. 
Final evaluation questionnaires completed (including evaluation of whether and how participants feel their views have 
changed – both public and stakeholders). 
Wrap up – senior GE speaker to explain what happens next, thank participants, and share one or two thoughts on what 
they will personally take away from the day. 
 
  
Ipsos MORI | A public dialogue on genomic medicine – FINAL – Public 94 
 
18-045132-01 | FINAL | Public | This work will be carried out in accordance with the requirements of the international quality standard for Market Research,  
ISO 20252, and with the Ipsos MORI Terms and Conditions which can be found at http://www.ipsos-mori.com/terms. © Ipsos MORI 2019 
 
The five stations 
NB: stimulus for this is intended to create metaphors to start discussions – we’ll be really clear that it’s Ipsos who have invented this.  We really need 
something tangible to help people think about the abstract issues which underlie potential changes to the social contract.   
Each of these areas brings to life a tension which has been identified at previous stages of the project – where participant expectations clash with 
what genomics must include, or where the exact way genomics should be rolled out needs to be bottomed out further.   
At each station the facilitator demonstrates our stimulus material and asks questions. 
 
 
Station #1:  Where is our data? 
Ipsos facilitator: Graham  
  Experts: Natalie Banner, Understanding Patient Data; Phil Booth, MedConfidential 
 
Uncertainty: What are your thoughts on the uncertainty of not being able to entirely pin down exactly which ‘genomics libraries’ our data might be 
part of, in future? 
● Stimulus:  A black box with icon of your GP/hospital on the outside.  Inside there are pictures/cards/things representing China, America, 
Pharma companies, researchers from different places. Examples of health record and digital versions of genomic data files.  Also include 
examples of face id on smart phones, posting on social media.  
● Discussion:   
o What is your data? Looking at the non-health data in the box. Thinking about data generally, how far do you know where data ends 
up? (e.g. your phone data, social media) How much of a concern, if any, is this to you? How does it affect your behaviour? 
o You give your data when you consent to genomic test at GP/hospital.  What actually is health data about you? Looking at different 
examples of data, health record, file of genomic data. Is this how you imagine genomic data to be? How do you imagine genomic 
data looks, how is it stored? Make the point that you need skills to reinterpret it.  Thinking about this kind of data, where do you 
think it might end up?  
o At previous stages in this project people have said they’re only happy with giving their data if it’s never “taken off the NHS servers” – 
well, GE is a kind of commercial company working alongside the NHS so it can be hard to generalise about ‘commercial access’; 
pharma companies and others are involved (as per stimulus) and there are other places data can end up – internationally, plus there 
may be a need to share with other private enterprises to develop genomic research or clinical treatments.    What kinds of “genomics 
libraries” are we imagining?  What, if anything, would have to be in place for you to feel comfortable that your data is in this place? 
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o What are the rules and expectations for how everyone should behave around data?   What conditions do you think 
people/organisations should have to comply with to show they are safe custodians or users of data about you? 
Reidentification and risk: Pushing participants further on the idea that reidentification is always going to be a possibility – are they really aware of the 
tradeoffs, and how do they think society should weigh these up? 
● Stimulus: Summary/picture/poster of Yaniv Erlich paper on how easy it is to reidentify 
● Discussion: Data security: Yes, it is illegal to reidentify data. But it’s not as simple as saying “I will only give my data if it can never be 
reidentified”. This kind of data will always be possible to reidentify with enough bioinformatics skill.  how happy are we to live with the risk 
that reidentification might be possible?   Do you need total certainty it won’t? How would you describe the level of risk? Who should assess 
that level? 
● What would reassure you that the chance is minimised? What governance processes do you think should be in place to deal with any 
breaches? How important is the ‘punishment’ for breaching data security for you? 
● Possible input from Edward Hocking/ MedConfidential? 
Summary for this station; on what the ‘social contract’ should include: Given that we can’t guarantee entire data security, what should we expect 
from patients, public, NHS, government in the new genomics rollout? How well can we adhere to the principles and values we came up with earlier? 
What kinds of safeguards around data can we expect? 
Comms: How much do we need to know about data security? Who’s responsible for informing us? 
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Station #2: The patient of the future 
 
Ipsos facilitator: Emily  
 Experts: Jonathan Montgomery, University College London; Jayne Spink, Genetic Alliance 
 
Personalised and predictive medicine: How will personalised medicine change the way we need to act as patients, clinicians, members of society?  
● Stimulus: Cartoon of future patient; labelled with features of the future patient. These are knowing their polygenic risk scores for risk of 
diabetes, therefore being monitored.  Having access to information about their children’s risk of diseases as well. Having access to 
professionals to give them advice on how to weigh up the risks and benefits of learning more about their genome.  They take a drug on 
prescription, their doctor gives them one rather than another because they know it works better for that particular patient. 
● Discussion: How will knowing more about our own profile change the way we behave as patients?   
● Will we have greater expectations of the NHS, greater expectations of our own personal responsibility?  How should the NHS system, 
government, clinicians, help patients in this world 
● What expectations do we have about the professionals who will help and advise us on learning about our genome? We’ve heard about 
genetic counsellors – there are only around 200 of these in the health service. How do we imagine the clinician of the future will be able to 
help us? 
● How do we prevent a dystopian reality where people are ‘blamed’ for having ‘bad genes’ or for not taking action to improve their own 
health?    
● How about uncertainty – a ‘learning healthcare service’ won’t necessarily be able to tell us exact risks for this or that, and genetic knowledge 
might lead to more complexity.  What should we be told about this?   What happens if the media are always telling us about certainty – “A 
gene for x” – is often much more deterministic than there is evidence for. How might this affect our perceptions of what’s possible in the 
system? How should we describe and deal with uncertainty? 
Free riders 
● Stimulus: free riders: cartoon of someone hitching a ride on a bus or similar – we explain the metaphor of a free rider. 
● Discussion: how does the system manage ‘free riders’? What’s fair? How do we communicate the idea of a ‘tipping point’ in data where 
everyone needs to get involved? 
Dystopian futures: Where are the limits of how we should use genetic information about ourselves?  
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● Stimulus:  Mock up headline “Dubai sequences genome of all city’s residents to prevent and mitigate diseases” and “Scientists can edit 
embryo to resist HIV infection” 
● Discussion: What rights should the patient of the future expect to have about making decisions based on the genetic information we know 
about ourselves? Are there some things we should not be allowed to know or to act on?  What do we think about risks such as making 
decisions which result in losing whole groups of people - those with Downs or deaf people for example? Is this a form of eugenics? Who 
should stop this happening?  
● In the Dubai example, it could potentially be mandatory to have your genome sequenced; in future it would be possible to segment or 
divide the population based on their genome. What do we think about population-wide screening, could it be used e.g. to deny healthcare 
to certain groups?  
● In the Chinese example, the scientist has edited a gene he claims would lead to greater protection against HIV. The babies have just been 
born but their health prognosis over the long term obviously isn’t known yet. How should we start to use this information in clinical practice? 
If we don’t know what might be the knock-on effect of editing one gene?  Or do we have the right NOT to do it, if we know we could, for 
example, edit out sickle cell anaemia genes? 
Summary on social contract: What changes about the roles and responsibility of all the players in the system?  
Comms: How far do we, as members of the public, need to know explicitly about any changes, or can we just infer them or experience them?  How 
far do we need a shared mandate for our roles and responsibilities in this changing world’? 
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Station #3 One big family? 
Does our understanding of what it means to be a patient change? 
 
 
Ipsos facilitator: Sam  
Experts: Ann Dalton, Sheffield Children’s Hospital; Fiona Crowe, Genomics England  
 
● Stimulus: The patient is the whole family -picture of a big family:  https://www.theguardian.com/science/2018/nov/25/woman-inherited-
fatal-illness-sue-doctors-groundbreaking-case-huntingtons  Article in the observer headline/summary, plus quote from the Huntington’s 
case lawyers –  “Should clinicians be legally obliged to consider the interests of anyone they are reasonably aware of who could be 
affected by genetic information – or is the protection afforded by current professional guidance enough?” also quote from the journalist 
“In future, a patient may be not just the person who provided a genetic sample, but may be defined as also those affected by that 
genetic sample” 
● Discussion: current GMC guidance says that one reason to disclose relevant information to others without consent is to “prevent serious 
harm in others” (current GMC guidance).  
 
Facilitator note: do give quick summary if think would help ppts grasp the issues: Guidance for doctors on disclosing personal information (adapted 
from General Medical Council guidance) 
Confidentiality is an important ethical and legal duty. Disclosing personal information breaches a doctor’s duty of confidentiality unless the following 
applies: 
a) The patient consents, implicitly or explicitly, for the sake of their own care or for local clinical audit  
b) The patient has given their explicit consent to disclosure for other purposes  
c) The disclosure is of overall benefit to a patient who lacks the capacity to consent  
d) The disclosure is required by law or the disclosure is permitted or has been approved under a statutory process that sets aside the 
common law duty of confidentiality  
e) The disclosure can be justified in the public interest 
 
●  What kind of serious harm would you imagine is relevant here – who should decide? 
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● Would you expect with genomics for familial information to be shared - by whom, and with whom?  Should clinicians be saying “familial 
risk” rather than disclosing individual info?  How should we separate personal clinical information from the familial information that led to 
it? What should patients be allowed to decide about the way their information is shared? Should a patient be able to decide not to let 
the family know? Does that put the doctor, a difficult position?  How about the researcher, if we are in a situation where the researcher 
might have a clinical duty to feedback findings which are relevant to care?  How do we do ‘the best healthcare we can’ under these 
circumstances? 
What support do we get?  
● Stimulus: comfy chair, genetic counselling leaflets?  
● Discussion: What should be the role of genetic counsellors and others involved in giving genetic information to patients? How important are 
they in the system? How should counsellors work with GPs and other healthcare professionals?  What happens if people can’t understand 
what they are ‘consenting’ to? How should we protect vulnerable people who give their data and take part in genomics – what systems do 
we need in place for this? If someone’s harmed, what redress do we expect? 
Summary on social contract: What changes about the roles of a patient and a member of society, in the new world of genomics? 
Comms: How far do we, as members of the public, need to know explicitly about any changes, or can we just infer them or experience them?  How 
far do we need a shared mandate for any changes to how we understand who is the patient? 
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Station #4 Show me the money  
 
 Ipsos facilitator: Polly Experts: Rose Grey, Cancer UK; Monika Preuss, DHSC  
 
How can we build trust in the NHS’ ability to deliver this service, in a time of austerity?  
Stimulus: Matt Hancock’s announcement on sequencing 5 million genomes 
Discussion: How should this play out in terms of the genomic counselling needed; how would we deliver this fairly?  What role should individual 
Trusts have in the rollout?  
Stimulus: The NHS – it’s not just one thing!  Plus, logos of pharma companies 
Discussion: Is it important that the public sees benefits in their care, at the same rate as we see advances in research?  Is it ‘fair’ for us to give our 
data if the balance of investment is in research and patients do not see the fruits of this for a long time?  Do you see this as something that benefits 
our research capacity, or our clinical capacity? Who should make money from genomics? Is it fair to expect private companies to invest and see no 
return?  How should government, society and others value the data which genomics relies upon?  Can we expect government to invest enough 
money on its own, to secure the benefits of genomic medicine? 
  
Private sector genomics 
Stimulus: 23and me leaflet offering Black Friday deals 
Discussion: What should be the role of data we collect ourselves, or share ourselves, in the system of genomics? Whose responsibility is it to protect 
us from risk? (e.g. giving all our data to online service where it’s not as secure or could be repurposed in future). 
 
Summary on social contract: How should we pay for genomics?  
Comms: What do we need to know about the way the genomics service is funded?  What would we need to be assured of to be happy with the 
NHS’ ability to deliver? 
 
Station #5 Blurred Lines:  research and clinical practice come together in genomics 
 
Ipsos facilitator: Sarah 
Experts: Michael Dunn, Wellcome Trust; Pauline Mullin, Medical Research Council  
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Different roles for clinicians/researchers? 
 
● Stimulus: a pretend/mock up blood test and consent form and/or two pictures, a researcher and a clinician, with a dividing line between 
them or an open door…a white coat someone can put on and a stethoscope so people can pretend to be researcher /clinician…  Then a 
sheet of cardboard with holes in – representing a blinkered version where only some information is available to the clinician and where 
the researcher has limited options to help the participant. We will explain how this works! 
 
● Discussion:  what does ‘being a good researcher/clinician/patient’ look like in this new world? What does ‘respect and care’ look like?  
 
● At the moment, (very crudely) the researcher doesn’t necessarily have to think about your care and the clinician doesn’t have to think 
about the research. They operate under different rules, for instance research requires HRA/REC approval and clinical practice doesn’t.  
Even if the patients don’t mind whether they are dealing with a researcher or clinician, the researcher or clinician may feel they have to 
be in one camp or another, because of the governance arrangements for each.   
 
● This is important for patients because researchers and clinicians having different roles affects the way data about you might be used and 
shared.   Ideally we might want our data to be as tightly controlled as it is in one research study – or only accessed by our clinician for 
our care.  But this new science needs our individual records to be linked up and for the old permissions for researchers / doctors to share 
information to change.  Are we happy with the trade off, or what reassurance would we need? Would we prefer the blinkered vision 
where data is shared less and we use the ‘old rules’ for clinicians and researchers?  We need to compare the limited roles with the tighter 
data restrictions with the more open data sharing and greater access from both sides. 
 
● Genomics can yield information which helps public health, by comparing individual data with other data, and can help individuals, if 
knowledge gained from a whole dataset is applied to one individual. What will change about the researcher’s role if something is 
discovered which impacts the care of the research participant?  How should clinicians keep abreast of what is happening in research?  
 
● Some academics have said that being a research participant in future won’t be about consenting once, e.g. when you have your blood 
taken.  It’ll be more like ‘entering a relationship’ where things about you are known, and into the future more things may be learned.   
How do you feel about that?  On consent, at previous events, you said “Don’t share data in ways which are not consented” – but we also 
recognised we can’t always consent to everything before it happens – in the case of the research discovering new information, how 
should researcher and clinician behave? What would be a reasonable and valid level of consent, if it’s not possible to identify all the ways 
the data might be used in future? To be valid it needs to be informed consent, voluntarily given. 
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Different roles for individuals in society 
● Stimulus: something representing a crowd. Picture of Field for the British Isles or similar? 
● Discussion: How much do you need to know about the fact that research – helping other patients – might need access to your individual 
level data? How do you feel if you don’t personally benefit from this?   What should you expect from doctors, researchers, as a ‘data donor’?  
Does this change if the study is done by a private company?    
Summary on social contract: What changes about the roles of a researcher and a clinician? How important is that change to you, the public – and 
what do you want to hear about it? 
Comms: What messages to we need to hear about the role of the individual, each of us, and society, all of us, in genomics? Who should be telling us 
about this?  
 
Individual feedback: stimulus material 
Public participants are also given a small booklet – My thoughts about genomics – to fill in as they rotate around these stations.   We reserve a few 
minutes to do this each time we rotate. Stakeholders can also have this, to record their reflections / any surprises at each station.  We collect them in 
at the end. Contents are as follows: 
● Page 1 Where is our data:   Genomics cannot guarantee a completely risk free sharing of data- because for it to work, data must be shared.  
What would need to be in place for you to accept the risk of reidentification from your data?   
● Page 2 The patient of the future:  What is fair when it comes to contributing data: should people be allowed to benefit from genomics if not 
contributing data themselves?   
● Page 3 One big family:  If, in the future, we have to think about the patient’s family as well as the patient, how does this change our 
relationship with our clinicians, and what we expect from healthcare?  How important is it that the public as a whole knows that how we think 
about ‘being a patient’ might change? 
● Page 4 Show me the money:  How should we pay for genomics?  What do you need to know about the way genomics is funded, to be 
reassured that the service is running well and fairly?  How far should the government be investing in genomics, and how far should others?  
● Page 5 Blurred Lines: What changes about the role of a researcher, and the role of a clinician? How important is it that the public knows about 
these changes?  
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